

	<b>PROPOSITION 65 STATEMENT OF CONFORMITY</b>	Document No.
		Page 1 of 23
		Issue Date: 11/09/2023
		Document Owner: H. Evans

Proposition 65 requires businesses to provide warnings to Californians about significant exposures to chemicals that cause cancer, birth defects or other reproductive harm. These chemicals can be in the products that Californians purchase, in their homes or workplaces, or that are released into the environment. By requiring that this information be provided, Proposition 65 enables Californians to make informed decisions about their exposures to these chemicals.

Proposition 65 also prohibits California businesses from knowingly discharging significant amounts of listed chemicals into sources of drinking water.

Proposition 65 requires California to publish a list of chemicals known to cause cancer, birth defects or other reproductive harm. This list, which must be updated at least once a year, has grown to include approximately 900 chemicals since it was first published in 1987.

Proposition 65 became law in November 1986, when California voters approved it by a 63-37 percent margin. The official name of Proposition 65 is the Safe Drinking Water and Toxic Enforcement Act of 1986.

COIL is committed to comply with regulatory compliance efforts and continues to monitor potential safety, health, and environmental impact of our products. We work with our suppliers to monitor impact on chemicals, preparations and articles supplied to us that are used to make our products that will meet California Proposition 65 standards.

COIL certify that their entire range of injection moulded Optical Products and packaging do not contain any of the latest OEHHA listed substances or are within the safe limits, if one has been adopted, and do not require a California Proposition 65 warning label. This statement is based on the current list of Proposition 65 at the date shown below.

**STATE OF CALIFORNIA**  
**ENVIRONMENTAL PROTECTION AGENCY - OFFICE OF ENVIRONMENTAL HEALTH HAZARD ASSESSMENT**  
**SAFE DRINKING WATER AND TOXIC ENFORCEMENT ACT OF 1986**  
**CHEMICALS KNOWN TO THE STATE TO CAUSE CANCER OR REPRODUCTIVE TOXICITY**  
**Last Updated: 21/04/2023**

In the Listing Mechanism column, "AB" denotes authoritative bodies, "SQE" denotes State's Qualified Experts, "FR" denotes formally required to be labelled or identified, and "LC" denotes Labour Code. For those chemicals for which the basis for listing documentation is available electronically, a hyperlink to the documentation is provided. The identification number indicated in the following list is the Chemical Abstracts Service (CAS) Registry Number. No CAS number is given when several substances are presented as a single listing. The date refers to the initial appearance of the chemical on the list. For those chemicals for which a no significant risk level (NSRL) for carcinogens or maximum allowable dose level (MADL) for reproductive toxicants has been adopted, it is denoted in the column, "NSRL or MADL." For those NSRLs or MADLs for which the risk assessment documentation is available electronically, a hyperlink to the documentation is provided.

Chemical	Type of Toxicity	Listing Mechanism	CAS No.	Date Listed	NSRL or MADL (µg/day)a
A-alpha-C (2-Amino-9H-pyrido[2,3-b]indole)	cancer	AB	26148-68-5	01-Jan-90	<a href="#">2</a>
Abiraterone acetate	developmental, female, male	<a href="#">FR</a>	154229-18-2	08-Apr-16	



# PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.

Page 2 of 23

Issue Date:  
11/09/2023

Document Owner:  
H. Evans

Acetaldehyde	cancer	SQE	75-07-0	01-Apr-88	90 (inhalation)
Acetamide	cancer	AB	60-35-5	01-Jan-90	<a href="#">10</a>
Acetazolamide	developmental	<a href="#">FR</a>	59-66-5	20-Aug-99	
Acetochlor	cancer	SQE	34256-82-1	01-Jan-89	
Acetohydroxamic acid	developmental	FR	546-88-3	01-Apr-90	
2-Acetylaminofluorene	cancer	SQE	53-96-3	01-Jul-87	<a href="#">0.2</a>
Acifluorfen sodium	cancer	AB	62476-59-9	01-Jan-90	
Acrylamide	cancer	AB	79-06-1	01-Jan-90	0.2
Acrylamide	developmental, male	<a href="#">AB</a>	79-06-1	25-Feb-11	<a href="#">140</a>
Acrylonitrile	cancer	FR	107-13-1	01-Jul-87	0.7
Actinomycin D [Basis for listing changed effective February 22, 2013]	cancer	<a href="#">FR</a>	50-76-0	01-Oct-89	<a href="#">0.00008</a>
Actinomycin D	developmental	FR	50-76-0	01-Oct-92	
AF-2;[2-(2-furyl)-3-(5-nitro-2-furyl)]acrylamide	cancer	SQE	3688-53-7	01-Jul-87	<a href="#">3</a>
Aflatoxins	cancer	SQE	---	01-Jan-88	
Alachlor	cancer	SQE	15972-60-8	01-Jan-89	
Alcoholic beverages	cancer	LC	---	29-Apr-11	
Alcoholic beverages, when associated with alcohol abuse	cancer	SQE	---	01-Jul-88	
Aldrin	cancer	SQE	309-00-2	01-Jul-88	0.04
All-trans retinoic acid	developmental	SQE	302-79-4	01-Jan-89	
<a href="#">Allyl chloride Delisted October 29, 1999 [Click here for the basis for delisting]</a>	cancer	AB	107-05-1	01-Jan-90	
Aloe vera, non-decolorized whole leaf extract	cancer	<a href="#">LC</a>	---	04-Dec-15	
Alprazolam	developmental	FR	28981-97-7	01-Jul-90	
Altretamine	developmental, male	<a href="#">FR</a>	645-05-6	20-Aug-99	
Amantadine hydrochloride	developmental	<a href="#">FR</a>	665-66-7	27-Feb-01	
Amikacin sulfate	developmental	FR	39831-55-5	01-Jul-90	
2-Aminoanthraquinone	cancer	LC	117-79-3	01-Oct-89	<a href="#">20</a>
p-Aminoazobenzene	cancer	AB	60-09-3	01-Jan-90	
o-Aminoazotoluene	cancer	SQE	97-56-3	01-Jul-87	<a href="#">0.2</a>
4-Aminobiphenyl (4-aminodiphenyl)	cancer	LC	92-67-1	27-Feb-87	<a href="#">0.03</a>
2-Amino-4-chlorophenol	cancer	<a href="#">LC</a>	95-85-2	13-Sep-19	
1-Amino-2,4-dibromoanthraquinone	cancer	<a href="#">AB</a>	81-49-2	26-Aug-97	
3-Amino-9-ethylcarbazole hydrochloride	cancer	SQE	6109-97-3	01-Jul-89	<a href="#">9</a>
2-Aminofluorene	cancer	<a href="#">SQE</a>	153-78-6	29-Jan-99	
Aminoglutethimide	developmental	FR	125-84-8	01-Jul-90	
Aminoglycosides	developmental	FR	---	01-Oct-92	
1-Amino-2-methylantraquinone	cancer	LC	82-28-0	01-Oct-89	<a href="#">5</a>
2-Amino-5-(5-nitro-2-furyl)-1,3,4-thiadiazole	cancer	SQE	712-68-5	01-Jul-87	<a href="#">0.04</a>
4-Amino-2-nitrophenol	cancer	<a href="#">SQE</a>	119-34-6	29-Jan-99	
Aminopterin	developmental, female	SQE	54-62-6	01-Jul-87	
Amiodarone hydrochloride	developmental, female, male	<a href="#">FR</a>	19774-82-4	26-Aug-97	
Amitraz	developmental	<a href="#">AB</a>	33089-61-1	30-Mar-99	
Amitrole	cancer	SQE	61-82-5	01-Jul-87	<a href="#">0.7</a>
Amoxapine	developmental	<a href="#">FR</a>	14028-44-5	15-May-98	
Amsacrine	cancer	<a href="#">LC</a>	51264-14-3	07-Aug-09	
<a href="#">tert Amyl methyl ether Delisted December 13, 2013 [Click here for the basis for delisting]</a>	developmental	<a href="#">LC</a>	994-05-8	18-Dec-09	
Anabolic steroids	female, male	FR	---	01-Apr-90	
Analgesic mixtures containing Phenacetin	cancer	LC	---	27-Feb-87	
Androstenedione	cancer	<a href="#">AB</a>	63-05-8	03-May-11	
Angiotensin converting enzyme (ACE) inhibitors	developmental	FR	---	01-Oct-92	
Aniline	cancer	AB	62-53-3	01-Jan-90	100



# PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.

Page **3** of **23**

Issue Date:  
11/09/2023

Document Owner:  
H. Evans

Aniline hydrochloride	cancer	<a href="#">AB</a>	142-04-1	15-May-98	
o-Anisidine	cancer	SQE	90-04-0	01-Jul-87	<a href="#">5</a>
o-Anisidine hydrochloride	cancer	SQE	134-29-2	01-Jul-87	<a href="#">7</a>
Anisindione	developmental	FR	117-37-3	01-Oct-92	
Anthraquinone	cancer	<a href="#">AB</a>	84-65-1	28-Sep-07	
Antimony oxide (Antimony trioxide)	cancer	AB	1309-64-4	01-Oct-90	
Aramite	cancer	SQE	140-57-8	01-Jul-87	<a href="#">20</a>
Areca nut	cancer	<a href="#">LC</a>	---	03-Feb-06	
Aristolochic acids	cancer	<a href="#">LC</a>	---	09-Jul-04	
Arsenic (inorganic arsenic compounds)	cancer	LC	--	27-Feb-87	0.06 (inhalation) 10 (except inhalation)
Arsenic (inorganic oxides)	developmental	<a href="#">SQE</a>	---	01-May-97	
Asbestos	cancer	LC	1332-21-4	27-Feb-87	100 fibers/day (inhalation)
Aspirin (NOTE: It is especially important not to use aspirin during the last three months of pregnancy, unless specifically directed to do so by a physician because it may cause problems in the unborn child or complications during delivery.)	developmental, female	SQE	50-78-2	01-Jul-90	
Atenolol	developmental	<a href="#">FR</a>	29122-68-7	26-Aug-97	
Atrazine	developmental, female	<a href="#">AB</a>	1912-24-9	15-Jul-16	<a href="#">100 (oral)</a>
Auramine	cancer	SQE	492-80-8	01-Jul-87	<a href="#">0.8</a>
Auranofin	developmental	<a href="#">FR</a>	34031-32-8	29-Jan-99	
Avermectin B1 (Abamectin)	developmental	<a href="#">AB</a>	71751-41-2	03-Dec-10	<a href="#">4.4</a>
Azacitidine	cancer	AB	320-67-2	01-Jan-92	
Azaserine	cancer	SQE	115-02-6	01-Jul-87	<a href="#">0.06</a>
Azathioprine	cancer	LC	446-86-6	27-Feb-87	<a href="#">0.4</a>
Azathioprine	developmental	FR	446-86-6	01-Sep-96	
Azobenzene	cancer	AB	103-33-3	01-Jan-90	6
Barbiturates	developmental	FR	---	01-Oct-92	
Beclomethasone dipropionate	developmental	<a href="#">FR</a>	5534-09-8	15-May-98	
Benomyl	developmental, male	SQE	17804-35-2	01-Jul-91	
Benthiavalicarb-isopropyl	cancer	<a href="#">AB</a>	177406-68-7	01-Jul-08	
Benz[a]anthracene	cancer	SQE	56-55-3	01-Jul-87	<a href="#">0.033 (oral)</a>
Benzene	cancer	LC	71-43-2	27-Feb-87	<a href="#">6.4 (oral)</a> <a href="#">13</a> (inhalation)
Benzene	developmental, male	<a href="#">SQE</a>	71-43-2	26-Dec-97	<a href="#">24 (oral)</a> <a href="#">49</a> (inhalation)
Benzidine [and its salts]	cancer	LC	92-87-5	27-Feb-87	0.001
Benzidine-based dyes	cancer	FR	---	01-Oct-92	
Benzodiazepines	developmental	FR	---	01-Oct-92	
Benzo[b]fluoranthene	cancer	SQE	205-99-2	01-Jul-87	<a href="#">0.096 (oral)</a>
Benzo[j]fluoranthene	cancer	SQE	205-82-3	01-Jul-87	<a href="#">0.11 (oral)</a>
Benzo[k]fluoranthene	cancer	SQE	207-08-9	01-Jul-87	
Benzofuran	cancer	AB	271-89-6	01-Oct-90	<a href="#">1.1</a>
Benzophenone	cancer	<a href="#">LC</a>	119-61-9	22-Jun-12	
Benzo[a]pyrene	cancer	SQE	50-32-8	01-Jul-87	0.06
Benzotrithloride	cancer	SQE	98-07-7	01-Jul-87	
Benzphetamine hydrochloride	developmental	FR	5411-22-3	01-Apr-90	
Benzyl chloride	cancer	AB	100-44-7	01-Jan-90	4
Benzyl violet 4B	cancer	SQE	1694-09-3	01-Jul-87	<a href="#">30</a>
Beryllium and beryllium compounds	cancer	SQE	---	01-Oct-87	
Beryllium					0.1
Beryllium oxide					0.1
Beryllium sulfate					0.0002
Betel quid with tobacco	cancer	AB	---	01-Jan-90	



# PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.

Page 4 of 23

Issue Date:  
11/09/2023

Document Owner:  
H. Evans

Betel quid without tobacco	cancer	<a href="#">LC</a>	---	03-Feb-06	
Bevacizumab	developmental, female	<a href="#">FR</a>	216974-75-3	08-Mar-19	
2,2-Bis(bromomethyl)-1,3-propanediol	cancer	AB	3296-90-0	01-May-96	
Bis(2-chloroethyl)ether	cancer	SQE	111-44-4	01-Apr-88	0.3
N,N-Bis(2-chloroethyl)-2-naphthylamine (Chlornapazine)	cancer	LC	494-03-1	27-Feb-87	
Bischloroethyl nitrosourea (BCNU) (Carmustine)	cancer	SQE	154-93-8	01-Jul-87	
Bischloroethyl nitrosourea (BCNU) (Carmustine)	developmental	FR	154-93-8	01-Jul-90	
Bis(chloromethyl)ether	cancer	LC	542-88-1	27-Feb-87	0.02
Bis(2-chloro-1-methylethyl)ether, technical grade	cancer	<a href="#">SQE</a>	---	29-Oct-99	
Bisphenol A (BPA)	female	<a href="#">SQE</a>	80-05-7	11-May-15	<a href="#">3 (dermal exposure from solid materials)</a>
Bisphenol A (BPA)	developmental	AB	80-05-7	18-Dec-20	
Bitumens, extracts of steam-refined and air refined	cancer	AB	---	01-Jan-90	
Bracken fern	cancer	AB	---	01-Jan-90	
Bromacil lithium salt	developmental	<a href="#">AB</a>	53404-19-6	18-May-99	
Bromacil lithium salt	male	<a href="#">SQE</a>	53404-19-6	17-Jan-03	
Bromate	cancer	<a href="#">AB</a>	15541-45-4	31-May-02	
Bromochloroacetic acid	cancer	<a href="#">AB</a>	5589-96-8	06-Apr-10	<a href="#">0.7</a>
1-Bromo-3-chloropropane	cancer	<a href="#">LC</a>	109-70-6	27-Jan-23	
Bromodichloroacetic acid	cancer	<a href="#">AB</a>	71133-14-7	29-Jul-16	<a href="#">0.95</a>
Bromodichloromethane	cancer	AB	75-27-4	01-Jan-90	5
Bromoethane	cancer	<a href="#">AB</a>	74-96-4	22-Dec-00	<a href="#">96</a>
Bromoform	cancer	AB	75-25-2	01-Apr-91	<a href="#">64</a>
1-Bromopropane (1-BP)	cancer	<a href="#">AB</a>	106-94-5	05-Aug-16	
1-Bromopropane (1-BP)	developmental, female, male	<a href="#">AB</a>	106-94-5	07-Dec-04	
2-Bromopropane (2-BP)	female, male	<a href="#">AB</a>	75-26-3	31-May-05	
Bromoxynil	developmental	FR	1689-84-5	01-Oct-90	
Bromoxynil octanoate	developmental	<a href="#">AB</a>	1689-99-2	18-May-99	
Butabarbital sodium	developmental	FR	143-81-7	01-Oct-92	
1,3-Butadiene	cancer	SQE	106-99-0	01-Apr-88	0.4
1,3-Butadiene	developmental, female, male	<a href="#">AB</a>	106-99-0	16-Apr-04	
1,4-Butanediol dimethanesulfonate (Busulfan)	cancer	LC	55-98-1	27-Feb-87	
1,4-Butanediol dimethanesulfonate (Busulfan)	developmental	SQE	55-98-1	01-Jan-89	
Butylated hydroxyanisole	cancer	AB	25013-16-5	01-Jan-90	4000
Butyl benzyl phthalate (BBP)d	developmental	<a href="#">AB</a>	85-68-7	02-Dec-05	<a href="#">1200 (oral)</a>
1-Butyl glycidyl ether	cancer	<a href="#">LC</a>	2426-08-6	27-Jan-23	
<a href="#">n-Butyl glycidyl ether Delisted April 4, 2014 [Click here for the basis for delisting]</a>	male	<a href="#">LC</a>	2426-08-6	07-Aug-09	
beta-Butyrolactone	cancer	SQE	3068-88-0	01-Jul-87	<a href="#">0.7</a>
Cacodylic acid	cancer	AB	75-60-5	01-May-96	
Cadmium	developmental, male	<a href="#">SQE</a>	---	01-May-97	<a href="#">4.1 (oral)</a>
Cadmium and cadmium compounds	cancer	SQE	---	01-Oct-87	
Cadmium					0.05 (inhalation)
Cannabis (marijuana) smoke	developmental	<a href="#">SQE</a>	---	03-Jan-20	
Caffeic acid	cancer	AB	331-39-5	01-Oct-94	
Captafol	cancer	<a href="#">SQE</a>	2425-06-1	01-Oct-88	<a href="#">5</a>
Captan	cancer	<a href="#">AB</a>	133-06-2	01-Jan-90	<a href="#">300</a>
Carbamazepine	developmental	<a href="#">FR</a>	298-46-4	29-Jan-99	
Carbaryl	cancer	<a href="#">AB</a>	63-25-2	05-Feb-10	



# PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.

Page 5 of 23

Issue Date:  
11/09/2023

Document Owner:  
H. Evans

Carbaryl [Basis for listing changed effective December 27, 2013]	developmental, female, male	<a href="#">AB</a>	63-25-2	07-Aug-09	
Carbazole	cancer	AB	86-74-8	01-May-96	<a href="#">4.1</a>
Carbon black (airborne, unbound particles of respirable size)	cancer	<a href="#">AB</a>	1333-86-4	21-Feb-03	
Carbon-black extracts	cancer	AB	---	01-Jan-90	
Carbon disulfide	developmental, female, male	SQE	75-15-0	01-Jul-89	
Carbon monoxide	developmental	SQE	630-08-0	01-Jul-89	
Carbon tetrachloride	cancer	SQE	56-23-5	01-Oct-87	5
Carboplatin	developmental	FR	41575-94-4	01-Jul-90	
N-Carboxymethyl-N-nitrosourea	cancer	<a href="#">SQE</a>	60391-92-6	25-Jan-02	<a href="#">0.7</a>
Catechol	cancer	<a href="#">AB</a>	120-80-9	15-Jul-03	
Ceramic fibers (airborne particles of respirable size)	cancer	AB	---	01-Jul-90	
Certain combined chemotherapy for lymphomas	cancer	LC	---	27-Feb-87	
Chenodiol	developmental	FR	474-25-9	01-Apr-90	
Chloral	cancer	<a href="#">LC</a>	75-87-6	13-Sep-13	
Chloral hydrate	cancer	<a href="#">LC</a>	302-17-0	13-Sep-13	
Chlorambucil	cancer	LC	305-03-3	27-Feb-87	<a href="#">0.002</a>
Chlorambucil	developmental	SQE	305-03-3	01-Jan-89	
<a href="#">Chloramphenicol Delisted January 4, 2013 [Click here for the basis for delisting]</a>	cancer	LC	<del>56-75-7</del>	<del>01-Oct-89</del>	
Chloramphenicol sodium succinate	cancer	<a href="#">FR</a>	982-57-0	27-Sep-13	
Chlorcyclizine hydrochloride	developmental	FR	1620-21-9	01-Jul-87	
Chlordane	cancer	SQE	57-74-9	01-Jul-88	0.5
Chlordecone (Kepone)	cancer	SQE	143-50-0	01-Jan-88	<a href="#">0.04</a>
Chlordecone (Kepone)	developmental	SQE	143-50-0	01-Jan-89	
Chlordiazepoxide	developmental	FR	58-25-3	01-Jan-92	
Chlordiazepoxide hydrochloride	developmental	FR	438-41-5	01-Jan-92	
Chlordimeform	cancer	SQE	6164-98-3	01-Jan-89	
Chlorendic acid	cancer	SQE	115-28-6	01-Jul-89	<a href="#">8</a>
Chlorinated paraffins (Average chain length, C12; approximately 60 percent chlorine by weight)	cancer	SQE	108171-26-2	01-Jul-89	<a href="#">8</a>
p-Chloroaniline	cancer	AB	106-47-8	01-Oct-94	<a href="#">1.5</a>
p-Chloroaniline hydrochloride	cancer	<a href="#">AB</a>	20265-96-7	15-May-98	<a href="#">1.9</a>
<a href="#">Chlorodibromomethane Delisted October 29, 1999 [Click here for the basis for delisting]</a>	cancer	AB	<del>124-48-1</del>	<del>01-Jan-90</del>	
Chloroethane (Ethyl chloride)	cancer	AB	75-00-3	01-Jul-90	<a href="#">150</a>
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine)	cancer	SQE	13010-47-4	01-Jan-88	
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine)	developmental	FR	13010-47-4	01-Jul-90	
1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU)	cancer	SQE	13909-09-6	01-Oct-88	
Chloroform	cancer	SQE	67-66-3	01-Oct-87	20 (oral) 40 (inhalation)
Chloroform [Basis for listing changed effective December 23, 2016]	developmental	<a href="#">SQE</a>	67-66-3	07-Aug-09	
Chloromethyl methyl ether (technical grade)	cancer	LC	107-30-2	27-Feb-87	<a href="#">0.3</a>
3-Chloro-2-methylpropene	cancer	SQE	563-47-3	01-Jul-89	<a href="#">5</a>
1-Chloro-4-nitrobenzene	cancer	<a href="#">SQE</a>	100-00-5	29-Oct-99	
2-Chloronitrobenzene	cancer	<a href="#">LC</a>	88-73-3	13-Sep-19	
4-Chloro-o-phenylenediamine	cancer	SQE	95-83-0	01-Jan-88	<a href="#">40</a>
Chloroprene	cancer	<a href="#">AB</a>	126-99-8	02-Jun-00	
2-Chloropropionic acid [Basis for listing changed effective December 20, 2013]	male	<a href="#">SQE</a>	598-78-7	07-Aug-09	
Chlorothalonil	cancer	SQE	1897-45-6	01-Jan-89	<a href="#">41</a>
p-Chloro-o-toluidine	cancer	AB	95-69-2	01-Jan-90	<a href="#">3</a>



# PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.

Page 6 of 23

Issue Date:  
11/09/2023

Document Owner:  
H. Evans

p-Chloro-o-toluidine, strong acid salts of	cancer	<a href="#">AB</a>	---	15-May-98	
p-Chloro-o-toluidine, hydrochloride					<a href="#">3.3</a>
5-Chloro-o-toluidine and its strong acid salts	cancer	<a href="#">SQE</a>	---	24-Oct-97	
Chlorotrianisene	cancer	FR	569-57-3	01-Sep-96	
p-chloro- $\alpha,\alpha,\alpha$ -trifluorotoluene (para-Chlorobenzotrifluoride, PCBTF)	cancer	AB	98-56-6	28-Jun-19	<a href="#">23</a>
Chlorozotocin	cancer	AB	54749-90-5	01-Jan-92	<a href="#">0.003</a>
Chlorpyrifos	developmental	<a href="#">SQE</a>	2921-88-2	15-Dec-17	<a href="#">0.58 (oral and inhalation)</a> <a href="#">7.2 (dermal)</a>
<a href="#">Chlorsulfuron-Delisted June 6, 2014</a> <a href="#">[Click here for the basis for delisting]</a>	developmental, female, male	AB	<del>64902-72-3</del>	<del>14-May-99</del>	
Chromium (hexavalent compounds)	cancer	LC	---	27-Feb-87	0.001 (inhalation)
Chromium (hexavalent compounds)	developmental, female, male	<a href="#">SQE</a>	---	19-Dec-08	<a href="#">8.2 (oral)</a>
Chrysene	cancer	AB	218-01-9	01-Jan-90	<a href="#">0.35 (oral)</a>
C.I. Acid Red 114	cancer	AB	6459-94-5	01-Jul-92	
C.I. Basic Red 9 monohydrochloride	cancer	SQE	569-61-9	01-Jul-89	<a href="#">3</a>
C.I. Direct Blue 15	cancer	<a href="#">AB</a>	2429-74-5	26-Aug-97	
C.I. Direct Blue 218	cancer	<a href="#">AB</a>	28407-37-6	26-Aug-97	<a href="#">50</a>
C.I. Disperse Yellow 3	cancer	<a href="#">SQE</a>	2832-40-8	08-Feb-13	
C.I. Solvent Yellow 14	cancer	<a href="#">AB</a>	842-07-9	15-May-98	
Ciclosporin (Cyclosporin A; Cyclosporine)	cancer	AB	59865-13-3; 79217-60-0	01-Jan-92	
Cidofovir	cancer, developmental, female, male	<a href="#">FR</a>	113852-37-2	29-Jan-99	
Cinnamyl anthranilate	cancer	SQE	87-29-6	01-Jul-89	<a href="#">200</a>
Cisplatin	cancer	SQE	15663-27-1	01-Oct-88	
Citrus Red No. 2	cancer	LC	6358-53-8	01-Oct-89	
Cladribine	developmental	FR	4291-63-8	01-Sep-96	
Clarithromycin	developmental	<a href="#">FR</a>	81103-11-9	01-May-97	
Clobetasol propionate	developmental, female	<a href="#">FR</a>	25122-46-7	15-May-98	
Clofibrate	cancer	FR	637-07-0	01-Sep-96	
Clomiphene citrate	cancer	<a href="#">FR</a>	50-41-9	24-May-13	
Clomiphene citrate	developmental	FR	50-41-9	01-Apr-90	
Clorazepate dipotassium	developmental	FR	57109-90-7	01-Oct-92	
CMNP (pyrazachlor)	cancer	<a href="#">AB</a>	6814-58-0	25-Aug-15	
Cobalt metal powder	cancer	AB	7440-48-4	01-Jul-92	
Cobalt [II] oxide	cancer	AB	1307-96-6	01-Jul-92	
Cobalt sulfate	cancer	<a href="#">LC</a>	10124-43-3	20-May-05	
Cobalt sulfate heptahydrate	cancer	<a href="#">AB</a>	10026-24-1	02-Jun-00	
Cocaine	developmental, female	SQE	50-36-2	01-Jul-89	
Coconut oil diethanolamine condensate (cocamide diethanolamine)	cancer	<a href="#">LC</a>	---	22-Jun-12	
Codeine phosphate	developmental	<a href="#">FR</a>	52-28-8	15-May-98	
Coke oven emissions	cancer	LC	---	27-Feb-87	0.3
Colchicine	developmental, male	FR	64-86-8	01-Oct-92	
Conjugated estrogens	cancer	LC	---	27-Feb-87	
Conjugated estrogens	developmental	FR	---	01-Apr-90	
Creosotes	cancer	SQE	---	01-Oct-88	
p-Cresidine	cancer	SQE	120-71-8	01-Jan-88	<a href="#">5</a>
Cumene	cancer	<a href="#">AB</a>	98-82-8	06-Apr-10	
Cupferron	cancer	SQE	135-20-6	01-Jan-88	<a href="#">3</a>
Cyanazine	developmental	FR	21725-46-2	01-Apr-90	
Cycasin	cancer	SQE	14901-08-7	01-Jan-88	
Cycloate	developmental	<a href="#">AB</a>	1134-23-2	19-Mar-99	
<a href="#">Cyclohexanol-Delisted January 25, 2002</a> <a href="#">[Click here for the basis for delisting]</a>	male	AB	<del>408-93-0</del>	<del>06-Nov-98</del>	
Cycloheximide	developmental	FR	66-81-9	01-Jan-89	



# PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.

Page 7 of 23

Issue Date:  
11/09/2023

Document Owner:  
H. Evans

Cyclopenta[cd]pyrene	cancer	<a href="#">LC</a>	27208-37-3	29-Apr-11	
Cyclophosphamide (anhydrous)	cancer	LC	50-18-0	27-Feb-87	<a href="#">1</a>
Cyclophosphamide (anhydrous)	developmental, female, male	SQE - developmental FR - female, male	50-18-0	01-Jan-89	
Cyclophosphamide (hydrated)	cancer	LC	6055-19-2	27-Feb-87	<a href="#">1</a>
Cyclophosphamide (hydrated)	developmental, female, male	SQE - developmental FR - female, male	6055-19-2	01-Jan-89	
Cyhexatin	developmental	FR	13121-70-5	01-Jan-89	
Cytarabine	developmental	SQE	147-94-4	01-Jan-89	
Cytembena	cancer	<a href="#">AB</a>	21739-91-3	15-May-98	
D&C Orange No. 17	cancer	AB	3468-63-1	01-Jul-90	
D&C Red No. 8	cancer	AB	2092-56-0	01-Oct-90	
D&C Red No. 9	cancer	AB	5160-02-1	01-Jul-90	<a href="#">100</a>
D&C Red No. 19	cancer	AB	81-88-9	01-Jul-90	
Dacarbazine	cancer	SQE	4342-03-4	01-Jan-88	<a href="#">0.01</a>
Dacarbazine	developmental	<a href="#">FR</a>	4342-03-4	29-Jan-99	
Daminozide	cancer	AB	1596-84-5	01-Jan-90	<a href="#">40</a>
Danazol	developmental	FR	17230-88-5	01-Apr-90	
Dantron (Chrysazin; 1,8-Dihydroxyanthraquinone)	cancer	AB	117-10-2	01-Jan-92	<a href="#">9</a>
Daunomycin	cancer	SQE	20830-81-3	01-Jan-88	
Daunorubicin hydrochloride	developmental	FR	23541-50-6	01-Jul-90	
<a href="#">2,4-D butyric acid [Click here for the basis for the removal of developmental endpoint, effective June 22, 2001]</a>	developmental, male	<a href="#">AB</a>	94-82-6	18-Jun-99	<a href="#">910</a>
DDD (Dichlorodiphenyl-dichloroethane)	cancer	SQE	72-54-8	01-Jan-89	2 (DDT, DDE, DDD in combination)
DDE (Dichlorodiphenyl-dichloroethylene)	cancer	SQE	72-55-9	01-Jan-89	2 (DDT, DDE, DDD in combination)
DDT (Dichlorodiphenyl-trichloroethane)	cancer	SQE	50-29-3	01-Oct-87	2 (DDT, DDE, DDD in combination)
o,p'-DDT	developmental, female, male	<a href="#">AB</a>	789-02-6	15-May-98	
p,p'-DDT	developmental, female, male	<a href="#">AB</a>	50-29-3	15-May-98	
DDVP (Dichlorvos)	cancer	SQE	62-73-7	01-Jan-89	2
Demeclocycline hydrochloride (internal use)	developmental	FR	64-73-3	01-Jan-92	
Des-ethyl atrazine (DEA)	developmental, female	<a href="#">AB</a>	6190-65-4	15-Jul-16	<a href="#">100 (oral)</a>
Des-isopropyl atrazine (DIA)	developmental, female	<a href="#">AB</a>	1007-28-9	15-Jul-16	<a href="#">100 (oral)</a>
N,N'-Diacetylbenzidine	cancer	LC	613-35-4	01-Oct-89	
2,4-Diaminoanisole	cancer	FR	615-05-4	01-Oct-90	<a href="#">30</a>
2,4-Diaminoanisole sulfate	cancer	SQE	39156-41-7	01-Jan-88	<a href="#">50</a>
2,4-Diamino-6-chloro-s-triazine (DACT)	developmental, female	<a href="#">AB</a>	3397-62-4	15-Jul-16	<a href="#">100 (oral)</a>
4,4'-Diaminodiphenyl ether (4,4'-Oxydianiline)	cancer	SQE	101-80-4	01-Jan-88	<a href="#">5</a>
2,4-Diaminotoluene	cancer	SQE	95-80-7	01-Jan-88	<a href="#">0.2</a>
<a href="#">Diaminotoluene (mixed) Delisted November, 20 2015 [Click here for the basis for delisting]</a>	cancer	AB	---	01-Jan-90	
Diazepam	developmental	FR	439-14-5	01-Jan-92	
Diazoaminobenzene	cancer	<a href="#">LC</a>	136-35-6	20-May-05	
Diazoxide	developmental	<a href="#">FR</a>	364-98-7	27-Feb-01	
Dibenz[a,h]acridine	cancer	SQE	226-36-8	01-Jan-88	
Dibenz[a,j]acridine	cancer	SQE	224-42-0	01-Jan-88	
Dibenzanthracenes	cancer	<a href="#">SQE</a>	---	26-Dec-14	
Dibenz[a,c]anthracene	cancer	<a href="#">SQE</a>	215-58-7	26-Dec-14	





# PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.

Page 8 of 23

Issue Date:  
11/09/2023

Document Owner:  
H. Evans

Dibenz[a,h]anthracene	cancer	SQE	53-70-3	01-Jan-88	<a href="#">0.2</a>
Dibenz[a,j]anthracene	cancer	<a href="#">SQE</a>	224-41-9	26-Dec-14	
7H-Dibenzo[c,g]carbazole	cancer	SQE	194-59-2	01-Jan-88	<a href="#">0.0030 (oral)</a>
Dibenzo[a,e]pyrene	cancer	SQE	192-65-4	01-Jan-88	
Dibenzo[a,h]pyrene	cancer	SQE	189-64-0	01-Jan-88	<a href="#">0.0054 (oral)</a>
Dibenzo[a,i]pyrene	cancer	SQE	189-55-9	01-Jan-88	<a href="#">0.0050 (oral)</a>
Dibenzo[a,l]pyrene	cancer	SQE	191-30-0	01-Jan-88	
Dibromoacetic acid	cancer	<a href="#">AB</a>	631-64-1	17-Jun-08	<a href="#">2.8</a>
Dibromoacetonitrile	cancer	<a href="#">AB</a>	3252-43-5	03-May-11	
1,2-Dibromo-3-chloropropane (DBCP)	cancer	FR	96-12-8	01-Jul-87	0.1
1,2-Dibromo-3-chloropropane (DBCP) [Basis for listing changed effective November 22, 2013]	male	<a href="#">FR</a>	96-12-8	27-Feb-87	<a href="#">3.1 (oral)</a> <a href="#">4.3</a> <a href="#">(inhalation)</a>
2,3-Dibromo-1-propanol	cancer	AB	96-13-9	01-Oct-94	
Dichloroacetic acid	cancer	AB	79-43-6	01-May-96	<a href="#">17</a>
Dichloroacetic acid	developmental, male	<a href="#">AB</a>	79-43-6	07-Aug-09	
p-Dichlorobenzene	cancer	SQE	106-46-7	01-Jan-89	20
3,3'-Dichlorobenzidine	cancer	SQE	91-94-1	01-Oct-87	0.6
3,3'-Dichlorobenzidine dihydrochloride	cancer	<a href="#">AB</a>	612-83-9	15-May-98	
1,1-Dichloro-2,2-bis(p-chlorophenyl)ethylene (DDE)	developmental, male	<a href="#">AB</a>	72-55-9	30-Mar-10	
1,4-Dichloro-2-butene	cancer	AB	764-41-0	01-Jan-90	
3,3'-Dichloro-4,4'-diamino-diphenyl ether	cancer	SQE	28434-86-8	01-Jan-88	
1,1-Dichloroethane	cancer	AB	75-34-3	01-Jan-90	<a href="#">100</a>
Dichloromethane (Methylene chloride)	cancer	SQE	75-09-2	01-Apr-88	50 200 <a href="#">(inhalation)</a>
1,4-Dichloro-2-nitrobenzene	cancer	<a href="#">LC</a>	89-61-2	13-Sep-19	
2,4-Dichloro-1-nitrobenzene	cancer	<a href="#">LC</a>	611-06-3	13-Sep-19	
Dichlorophene	developmental	<a href="#">AB</a>	97-23-4	27-Apr-99	
Dichlorophenamide	developmental	<a href="#">FR</a>	120-97-8	27-Feb-01	
1,2-Dichloropropane	cancer	AB	78-87-5	01-Jan-90	<a href="#">9.7</a>
1,3-Dichloro-2-propanol (1,3-DCP)	cancer	<a href="#">SQE</a>	96-23-1	08-Oct-10	
1,3-Dichloropropene	cancer	SQE	542-75-6	01-Jan-89	<a href="#">3.7 (oral and inhalation)</a>
Diclofop-methyl	cancer	<a href="#">AB</a>	51338-27-3	06-Apr-10	
Diclofop methyl	developmental	<a href="#">AB</a>	51338-27-3	05-Mar-99	
Dicumarol	developmental	FR	66-76-2	01-Oct-92	
Dieldrin	cancer	SQE	60-57-1	01-Jul-88	0.04
<a href="#">Dieneestrol Delisted January 4, 2013 (Click here for the basis for delisting)</a>	<del>cancer</del>	<del>LC</del>	<del>84-17-3</del>	<del>01-Jan-90</del>	
Diepoxybutane	cancer	SQE	1464-53-5	01-Jan-88	
Diesel engine exhaust	cancer	AB	---	01-Oct-90	
Diethanolamine	cancer	<a href="#">LC</a>	111-42-2	22-Jun-12	
Di(2-ethylhexyl)phthalate (DEHP)	cancer	SQE	117-81-7	01-Jan-88	<a href="#">310</a>
Di(2-ethylhexyl)phthalate (DEHP)	developmental, male	<a href="#">AB</a>	117-81-7	24-Oct-03	
Adultb					<a href="#">4200 (intravenous)</a>
Infant boys, age 29 days to 24 monthsb					<a href="#">600 (intravenous)</a>
Neonatal infant boys, age 0 to 28 daysb					<a href="#">210 (intravenous)</a>
Adultb					<a href="#">410 (oral)</a>
Infant boys, age 29 days to 24 monthsb					<a href="#">58 (oral)</a>
Neonatal infant boys, age 0 to 28 daysb					<a href="#">20 (oral)</a>
1,2-Diethylhydrazine	cancer	SQE	1615-80-1	01-Jan-88	
Diethylstilbestrol (DES)	cancer	LC	56-53-1	27-Feb-87	<a href="#">0.002</a>
Diethylstilbestrol (DES)	developmental	FR	56-53-1	01-Jul-87	
Diethyl sulfate	cancer	SQE	64-67-5	01-Jan-88	
Diflunisal	developmental, female	<a href="#">FR</a>	22494-42-4	29-Jan-99	





# PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.

Page 9 of 23

Issue Date:  
11/09/2023

Document Owner:  
H. Evans

<a href="#">Diglycidyl ether Delisted April 4, 2014 [Click here for the basis for delisting]</a>	male	LC	2238-07-5	07-Aug-09	
Diglycidyl resorcinol ether (DGRE)	cancer	SQE	101-90-6	01-Jul-89	<a href="#">0.4</a>
Dihydroergotamine mesylate	developmental	FR	6190-39-2	01-May-97	
Dihydrosafrole	cancer	SQE	94-58-6	01-Jan-88	<a href="#">20</a>
Di-isodecyl phthalate (DIDP)	developmental	AB	68515-49-1/ 26761-40-0	20-Apr-07	<a href="#">2200</a>
Diisononyl phthalate (DINP)	cancer	SQE	---	20-Dec-13	<a href="#">146</a>
Diisopropyl sulfate	cancer	AB	2973-10-6	01-Apr-93	
Diltiazem hydrochloride	developmental	FR	33286-22-5	27-Feb-01	
3,3'-Dimethoxybenzidine (o-Dianisidine)	cancer	SQE	119-90-4	01-Jan-88	<a href="#">0.15</a>
3,3'-Dimethoxybenzidine dihydrochloride	cancer	AB	20325-40-0	01-Oct-90	<a href="#">0.19</a>
3,3'-Dimethoxybenzidine-based dyes metabolized to 3,3'-dimethoxybenzidine	cancer	AB	---	11-Jun-04	
N,N-Dimethylacetamide	cancer	LC	127-19-5	13-Sep-19	
<a href="#">N,N-Dimethylacetamide [Click here for the basis for addition of male reproductive endpoint, effective December 20, 2013]</a>	developmental, male	SQE	127-19-5	21-May-10	
4-Dimethylaminoazobenzene	cancer	SQE	60-11-7	01-Jan-88	<a href="#">0.2</a>
trans-2-[(Dimethylamino)methylimino]-5-[2-(5-nitro-2-furyl)vinyl]-1,3,4-oxadiazole	cancer	SQE	55738-54-0	01-Jan-88	<a href="#">2</a>
7,12-Dimethylbenz(a)anthracene	cancer	AB	57-97-6	01-Jan-90	<a href="#">0.003</a>
3,3'-Dimethylbenzidine (ortho-Tolidine)	cancer	SQE	119-93-7	01-Jan-88	<a href="#">0.044</a>
3,3'-Dimethylbenzidine-based dyes metabolized to 3,3'-dimethylbenzidine	cancer	AB	---	11-Jun-04	
3,3'-Dimethylbenzidine dihydrochloride	cancer	AB	612-82-8	01-Apr-92	<a href="#">0.059</a>
Dimethylcarbonyl chloride	cancer	SQE	79-44-7	01-Jan-88	<a href="#">0.05</a>
N,N-Dimethylformamide	cancer	LC	68-12-2	27-Oct-17	
1,1-Dimethylhydrazine (UDMH)	cancer	LC	57-14-7	01-Oct-89	
1,2-Dimethylhydrazine	cancer	SQE	540-73-8	01-Jan-88	<a href="#">0.001</a>
2,6-Dimethyl-N-nitrosomorpholine (DMNM)	cancer	SQE	1456-28-6	08-Feb-13	
Dimethyl sulfate	cancer	SQE	77-78-1	01-Jan-88	
N,N-Dimethyl-p-toluidine	cancer	AB	99-97-8	02-May-14	
Dimethylvinylchloride	cancer	SQE	513-37-1	01-Jul-89	<a href="#">20</a>
Di-n-butyl phthalate (DBP)	developmental, female, male	AB	84-74-2	02-Dec-05	<a href="#">8.7</a>
Di-n-hexyl phthalate (DnHP)	female, male	AB	84-75-3	02-Dec-05	<a href="#">2200 (oral)</a>
m-Dinitrobenzene	male	AB	99-65-0	01-Jul-90	<a href="#">38</a>
o-Dinitrobenzene	male	AB	528-29-0	01-Jul-90	
p-Dinitrobenzene	male	AB	100-25-4	01-Jul-90	
3,7-Dinitrofluoranthene	cancer	AB	105735-71-5	26-Aug-97	
3,9-Dinitrofluoranthene	cancer	AB	22506-53-2	26-Aug-97	
1,3-Dinitropyrene	cancer	LC	75321-20-9	02-Nov-12	
1,6-Dinitropyrene	cancer	AB	42397-64-8	01-Oct-90	
1,8-Dinitropyrene	cancer	AB	42397-65-9	01-Oct-90	
2,4-Dinitrotoluene	cancer	SQE	121-14-2	01-Jul-88	<a href="#">2</a>
2,4-Dinitrotoluene	male	AB	121-14-2	20-Aug-99	
2,6-Dinitrotoluene	cancer	SQE	606-20-2	01-Jul-95	
2,6-Dinitrotoluene	male	AB	606-20-2	20-Aug-99	
Dinitrotoluene (technical grade)	female, male	AB	---	20-Aug-99	
Dinitrotoluene mixture, 2,4-/2,6-	cancer	AB	---	01-May-96	
Dinocap	developmental	FR	39300-45-3	01-Apr-90	
Dinoseb	developmental, male	FR	88-85-7	01-Jan-89	
Di-n-propyl isocinchomeronate (MGK Repellent 326)	cancer	AB	136-45-8	01-May-96	
1,4-Dioxane	cancer	SQE	123-91-1	01-Jan-88	<a href="#">30</a>
Diphenylhydantoin (Phenytoin)	cancer	SQE	57-41-0	01-Jan-88	
Diphenylhydantoin (Phenytoin)	developmental	SQE	57-41-0	01-Jul-87	
Diphenylhydantoin (Phenytoin), sodium salt	cancer	SQE	630-93-3	01-Jan-88	



# PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.

Page **10** of **23**

Issue Date:  
11/09/2023

Document Owner:  
H. Evans

Direct Black 38 (technical grade)	cancer	SQE	1937-37-7	01-Jan-88	<a href="#">0.09</a>
Direct Blue 6 (technical grade)	cancer	SQE	2602-46-2	01-Jan-88	<a href="#">0.09</a>
Direct Brown 95 (technical grade)	cancer	SQE	16071-86-6	01-Oct-88	<a href="#">0.1</a>
Disodium cyanodithioimidocarbonate	developmental	<a href="#">AB</a>	138-93-2	30-Mar-99	<a href="#">56 (oral)</a> <a href="#">170 (oral) as 32% pesticidal formulation</a>
Disperse Blue 1	cancer	AB	2475-45-8	01-Oct-90	<a href="#">200</a>
Diuron	cancer	<a href="#">AB</a>	330-54-1	31-May-02	
Doxorubicin hydrochloride (Adriamycin)	cancer	SQE	25316-40-9	01-Jul-87	
Doxorubicin hydrochloride (Adriamycin)	developmental, male	<a href="#">FR</a>	25316-40-9	29-Jan-99	
Doxycycline (internal use)	developmental	FR	564-25-0	01-Jul-90	
Doxycycline calcium (internal use)	developmental	FR	94088-85-4	01-Jan-92	
Doxycycline hyclate (internal use)	developmental	FR	24390-14-5	01-Oct-91	
Doxycycline monohydrate (internal use)	developmental	FR	17086-28-1	01-Oct-91	
<a href="#">2,4-DP (dichloroprop) Delisted January 25, 2002 [Click here for the basis for delisting]</a>	developmental	AB	120-36-5	27-Apr-99	
Emissions from combustion of coal	cancer	<a href="#">AB</a>	---	07-Aug-13	
Emissions from high-temperature unrefined rapeseed oil	cancer	<a href="#">AB</a>	---	03-Jan-14	
Endrin	developmental	<a href="#">AB</a>	72-20-8	15-May-98	
Environmental tobacco smoke (ETS)	developmental	<a href="#">SQE</a>	---	09-Jun-06	
Epichlorohydrin	cancer	SQE	106-89-8	01-Oct-87	9
Epichlorohydrin	male	AB	106-89-8	01-Sep-96	
Epoxiconazole	cancer	<a href="#">AB</a>	135319-73-2	15-Apr-11	
Ergotamine tartrate	developmental	FR	379-79-3	01-Apr-90	
Erionite	cancer	SQE	12510-42-8; 66733-21-9	01-Oct-88	
Estradiol 17B	cancer	SQE	50-28-2	01-Jan-88	<a href="#">0.02</a>
Estragole	cancer	<a href="#">SQE</a>	140-67-0	29-Oct-99	
Estrogens, steroidal	cancer	<a href="#">LC</a>	---	19-Aug-05	
Estrogen-progestogen (combined) used as menopausal therapy	cancer	<a href="#">LC</a>	---	04-Nov-11	
Estrone	cancer	SQE	53-16-7	01-Jan-88	
Estopipate	cancer, developmental	<a href="#">FR</a>	7280-37-7	26-Aug-97	
Ethinylestradiol	cancer	SQE	57-63-6	01-Jan-88	
Ethionamide	developmental	<a href="#">FR</a>	536-33-4	26-Aug-97	
Ethoprop	cancer	<a href="#">AB</a>	13194-48-4	27-Feb-01	
Ethyl acrylate	cancer	SQE	140-88-5	01-Jul-89	
Ethyl alcohol in alcoholic beverages	developmental	SQE	---	01-Oct-87	
Ethylbenzene	cancer	<a href="#">AB</a>	100-41-4	11-Jun-04	<a href="#">54 (inhalation)</a> <a href="#">41 (oral)</a>
<a href="#">Ethyl tert butyl ether Delisted December 13, 2013 [Click here for the basis for delisting]</a>	male	LC	637-92-3	18-Dec-09	
Ethyl dipropylthiocarbamate	developmental	<a href="#">AB</a>	759-94-4	27-Apr-99	<a href="#">700 (oral and inhalation)</a> <a href="#">6700 (dermal)</a>
Ethyl-4,4'-dichlorobenzilate	cancer	AB	510-15-6	01-Jan-90	<a href="#">7</a>
Ethylene dibromide	cancer	FR	106-93-4	01-Jul-87	0.2 (oral) 3 (inhalation)
Ethylene dibromide	developmental, male	<a href="#">AB</a>	106-93-4	15-May-98	
Ethylene dichloride (1,2-Dichloroethane)	cancer	SQE	107-06-2	01-Oct-87	10
Ethylene glycol (ingested)	developmental	<a href="#">AB</a>	107-21-1	19-Jun-15	<a href="#">8700 (oral)</a>
Ethylene glycol monoethyl ether	developmental, male	SQE	110-80-5	01-Jan-89	<a href="#">750 (oral)</a> <a href="#">960 (inhalation)</a>



# PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.

Page **11** of **23**

Issue Date:  
11/09/2023

Document Owner:  
H. Evans

Ethylene glycol monoethyl ether acetate	developmental, male	AB	111-15-9	01-Jan-93	<a href="#">1100 (oral)</a> <a href="#">1400 (inhalation)</a>
Ethylene glycol monomethyl ether	developmental, male	SQE	109-86-4	01-Jan-89	<a href="#">63 (oral)</a>
Ethylene glycol monomethyl ether acetate	developmental, male	AB	110-49-6	01-Jan-93	<a href="#">98 (oral)</a>
Ethyleneimine (Aziridine)	cancer	SQE	151-56-4	01-Jan-88	<a href="#">0.01</a>
Ethylene oxide	cancer	FR	75-21-8	01-Jul-87	2
Ethylene oxide [Basis for listing changed effective November 22, 2013]	female	<a href="#">FR</a>	75-21-8	27-Feb-87	20
Ethylene oxide [Basis for listing changed effective November 22, 2013]	developmental, male	<a href="#">FR</a>	75-21-8	07-Aug-09	20
Ethylene thiourea	cancer	AB	96-45-7	01-Jan-88	<a href="#">20</a>
Ethylene thiourea	developmental	SQE	96-45-7	01-Jan-93	
<a href="#">2-Ethylhexanoic acid - Delisted December 13, 2013 [Click here for the basis for delisting]</a>	developmental	LC	<del>149-57-5</del>	<del>07-Aug-09</del>	
2-Ethylhexyl acrylate	cancer	<a href="#">LC</a>	103-11-7	17-Dec-21	
Ethyl methanesulfonate	cancer	SQE	62-50-0	01-Jan-88	
Etodolac	developmental, female	<a href="#">FR</a>	41340-25-4	20-Aug-99	
Etoposide	cancer	<a href="#">LC</a>	33419-42-0	04-Nov-11	
Etoposide	developmental	FR	33419-42-0	01-Jul-90	
Etoposide in combination with cisplatin and bleomycin	cancer	<a href="#">LC</a>	---	04-Nov-11	
Etretinate	developmental	SQE	54350-48-0	01-Jul-87	
Fenoxaprop ethyl	developmental	<a href="#">AB</a>	66441-23-4	26-Mar-99	
Fenoxycarb	cancer	<a href="#">AB</a>	72490-01-8	02-Jun-00	
Filgrastim	developmental	<a href="#">FR</a>	121181-53-1	27-Feb-01	
Fluazifop butyl	developmental	<a href="#">AB</a>	69806-50-4	06-Nov-98	
Flunisolide	developmental, female	<a href="#">FR</a>	3385-03-3	15-May-98	
Fluorouracil	developmental	SQE	51-21-8	01-Jan-89	
Fluoxymesterone	developmental	FR	76-43-7	01-Apr-90	
Flurazepam hydrochloride	developmental	FR	1172-18-5	01-Oct-92	
Flurbiprofen	developmental, female	<a href="#">FR</a>	5104-49-4	20-Aug-99	
Flutamide	developmental	FR	13311-84-7	01-Jul-90	
Fluticasone propionate	developmental	<a href="#">FR</a>	80474-14-2	15-May-98	
Fluvalinate	developmental	<a href="#">AB</a>	69409-94-5	06-Nov-98	
Folpet	cancer	SQE	133-07-3	01-Jan-89	200
Formaldehyde (gas)	cancer	SQE	50-00-0	01-Jan-88	40
2-(2-Formylhydrazino)-4-(5-nitro-2-furyl)thiazole	cancer	SQE	3570-75-0	01-Jan-88	<a href="#">0.3</a>
Fumonisin B1	cancer	<a href="#">AB</a>	116355-83-0	14-Nov-03	
Furan	cancer	AB	110-00-9	01-Oct-93	
Furazolidone	cancer	AB	67-45-8	01-Jan-90	
Furfuryl alcohol	cancer	<a href="#">AB</a>	98-00-0	30-Sep-16	
Furmecycloz	cancer	AB	60568-05-0	01-Jan-90	20
Fusarin C	cancer	SQE	79748-81-5	01-Jul-95	
Gallium arsenide	cancer	<a href="#">LC</a>	1303-00-0	01-Aug-08	
Ganciclovir	cancer, developmental, male	<a href="#">FR</a>	82410-32-0	26-Aug-97	
Ganciclovir sodium	developmental, male	<a href="#">FR</a>	107910-75-8	26-Aug-97	
Gasoline engine exhaust (condensates/extracts)	cancer	AB	---	01-Oct-90	
Gemfibrozil	cancer	<a href="#">FR</a>	25812-30-0	22-Dec-00	
Gemfibrozil	female, male	<a href="#">FR</a>	25812-30-0	20-Aug-99	
Gentian violet (Crystal violet)	cancer	SQE	548-62-9	23-Nov-18	



# PROPOSITION 65 STATEMENT OF CONFORMITY


Document No.

Page **12** of **23**

Issue Date:  
11/09/2023

Document Owner:  
H. Evans

Glass wool fibers (inhalable and biopersistent)	cancer	AB	---	01-Jul-90	
Glu-P-1 (2-Amino-6-methylpyrido[1,2-a:3',2'-d]imidazole)	cancer	AB	67730-11-4	01-Jan-90	<a href="#">0.1</a>
Glu-P-2 (2-Aminodipyrdo[1,2-a:3',2'-d]imidazole)	cancer	AB	67730-10-3	01-Jan-90	<a href="#">0.5</a>
Glycidaldehyde	cancer	SQE	765-34-4	01-Jan-88	
Glycidol	cancer	AB	556-52-5	01-Jul-90	<a href="#">0.54</a>
Glycidyl methacrylate	cancer	<a href="#">LC</a>	106-91-2	27-Jan-23	
Glyphosate	cancer	<a href="#">LC</a>	1071-83-6	07-Jul-17	<a href="#">1100</a>
Goldenseal root powder	cancer	<a href="#">LC</a>	---	04-Dec-15	
Goserelin acetate	developmental, female, male	<a href="#">FR</a>	65807-02-5	26-Aug-97	
Griseofulvin	cancer	AB	126-07-8	01-Jan-90	
Gyromitrin (Acetaldehyde methylformylhydrazine)	cancer	SQE	16568-02-8	01-Jan-88	<a href="#">0.07</a>
Halazepam	developmental	FR	23092-17-3	01-Jul-90	
Halobetasol propionate	developmental	<a href="#">FR</a>	66852-54-8	20-Aug-99	
Haloperidol	developmental, female	<a href="#">FR</a>	52-86-8	29-Jan-99	
Halothane	developmental	FR	151-67-7	01-Sep-96	
HC Blue 1	cancer	SQE	2784-94-3	01-Jul-89	<a href="#">10</a>
Heptachlor	cancer	SQE	76-44-8	01-Jul-88	0.2
Heptachlor	developmental	<a href="#">AB</a>	76-44-8	20-Aug-99	
Heptachlor epoxide	cancer	SQE	1024-57-3	01-Jul-88	0.08
Herbal remedies containing plant species of the genus Aristolochia	cancer	<a href="#">LC</a>	---	09-Jul-04	
Hexachlorobenzene	cancer	SQE	118-74-1	01-Oct-87	0.4
Hexachlorobenzene	developmental	SQE	118-74-1	01-Jan-89	
Hexachlorobutadiene	cancer	<a href="#">AB</a>	87-68-3	03-May-11	
Hexachlorocyclohexane (technical grade)	cancer	SQE	---	01-Oct-87	0.2
Hexachlorocyclohexane (alpha isomer)					0.3
Hexachlorocyclohexane (beta isomer)					0.5
Hexachlorocyclohexane (gamma isomer)					0.6
Hexachlorodibenzodioxin	cancer	SQE	34465-46-8	01-Apr-88	0.0002
Hexachloroethane	cancer	AB	67-72-1	01-Jul-90	<a href="#">20</a>
2,4-Hexadienal (89% trans, trans isomer; 11% cis, trans isomer)	cancer	<a href="#">AB</a>	---	04-Mar-05	
Hexafluoroacetone [Basis for listing changed effective June 6, 2014]	developmental, male	<a href="#">LC SQE</a>	684-16-2	01-Aug-08	
Hexamethylphosphoramide	cancer	SQE	680-31-9	01-Jan-88	
Hexamethylphosphoramide	male	AB	680-31-9	01-Oct-94	
n-Hexane	male	<a href="#">SQE</a>	110-54-3	15-Dec-17	<a href="#">28,000 (oral)</a> <a href="#">20,000 (inhalation)</a>
2,5-Hexanedione	male	<a href="#">SQE</a>	110-13-4	04-Dec-15	
Histrelin acetate	developmental	<a href="#">FR</a>	---	15-May-98	
Hydramethylnon	developmental, male	<a href="#">AB</a>	67485-29-4	05-Mar-99	<a href="#">120 (oral)</a>
Hydrazine	cancer	SQE	302-01-2	01-Jan-88	0.04
Hydrazine sulfate	cancer	SQE	10034-93-2	01-Jan-88	0.2
Hydrazobenzene (1,2-Diphenylhydrazine)	cancer	SQE	122-66-7	01-Jan-88	<a href="#">0.8</a>
Hydrogen cyanide (HCN) and cyanide salts (CN salts)	male	<a href="#">AB</a>	---	05-Jul-13	
Cyanide salts that readily dissociate in solution (expressed as cyanide)f					<a href="#">9.8</a>
Hydrogen cyanidef					<a href="#">10 (oral)</a>
Sodium cyanidef					<a href="#">19 (oral)</a>
Potassium cyanidef					<a href="#">25 (oral)</a>
1-Hydroxyanthraquinone	cancer	<a href="#">LC</a>	129-43-1	27-May-05	
Hydroxyurea	developmental	<a href="#">FR</a>	127-07-1	01-May-97	



# PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.

Page **13** of **23**

Issue Date:  
11/09/2023

Document Owner:  
H. Evans

Idarubicin hydrochloride	developmental, male	<a href="#">FR</a>	57852-57-0	20-Aug-99	
Ifosfamide	developmental	FR	3778-73-2	01-Jul-90	
Iodine-131	developmental	SQE	10043-66-0	01-Jan-89	
Imazail	cancer	<a href="#">AB</a>	35554-44-0	20-May-11	<a href="#">11</a>
Indeno[1,2,3-cd]pyrene	cancer	SQE	193-39-5	01-Jan-88	
Indium phosphide	cancer	<a href="#">AB</a>	22398-80-7	27-Feb-01	
Indium tin oxide	cancer	<a href="#">LC</a>	50926-11-9	19-Mar-21	
IQ (2-Amino-3-methylimidazo[4,5-f]quinoline)	cancer	AB	76180-96-6	01-Apr-90	<a href="#">0.5</a>
Iprodione	cancer	AB	36734-19-7	01-May-96	
Iprovalicarb	cancer	<a href="#">AB</a>	140923-17-7/ 140923-25-7	01-Jun-07	
Iron dextran complex	cancer	SQE	9004-66-4	01-Jan-88	
Isobutyl nitrite	cancer	AB	542-56-3	01-May-96	<a href="#">7.4</a>
Isoprene	cancer	AB	78-79-5	01-May-96	
Isopyrazam	cancer	<a href="#">AB</a>	881685-58-1	24-Jul-12	
<a href="#">Isosafrole Delisted December 8, 2006 (Click here for the basis for delisting)</a>	cancer	LC	120-58-1	01-Oct-89	
Isotretinoin	developmental	SQE	4759-48-2	01-Jul-87	
Isoxaflutole	cancer	<a href="#">AB</a>	141112-29-0	22-Dec-00	
Kresoxim-methyl	cancer	<a href="#">AB</a>	143390-89-0	03-Feb-12	
Lactofen	cancer	SQE	77501-63-4	01-Jan-89	
Lasiocarpine	cancer	SQE	303-34-4	01-Apr-88	<a href="#">0.09</a>
Lead [Basis for listing changed effective November 22, 2013]	developmental, female, male	<a href="#">FR</a>	---	27-Feb-87	0.5
Lead and lead compounds	cancer	AB	---	01-Oct-92	
Lead					<a href="#">15 (oral)</a>
Lead acetate	cancer	SQE	301-04-2	01-Jan-88	<a href="#">23 (oral)</a>
Lead phosphate	cancer	SQE	7446-27-7	01-Apr-88	<a href="#">58 (oral)</a>
Lead subacetate	cancer	LC	1335-32-6	01-Oct-89	<a href="#">41 (oral)</a>
Leather dust	cancer	<a href="#">LC</a>	---	29-Apr-11	
Leucomalachite green	cancer	<a href="#">LC</a>	129-73-7	21-Apr-23	
Leuprolide acetate	developmental, female, male	<a href="#">FR</a>	74381-53-6	26-Aug-97	
Levodopa	developmental	<a href="#">FR</a>	59-92-7	29-Jan-99	
Levonorgestrel implants	female	<a href="#">FR</a>	797-63-7	15-May-98	
Lindane and other hexachlorocyclohexane isomers	cancer	LC	---	01-Oct-89	
Linuron	developmental	<a href="#">AB</a>	330-55-2	19-Mar-99	<a href="#">460</a>
Lithium carbonate	developmental	FR	554-13-2	01-Jan-91	
Lithium citrate	developmental	FR	919-16-4	01-Jan-91	
Lorazepam	developmental	FR	846-49-1	01-Jul-90	
Lovastatin	developmental	FR	75330-75-5	01-Oct-92	
Lynestrenol	cancer	<a href="#">AB</a>	52-76-6	27-Feb-01	
Malathion	cancer	<a href="#">LC</a>	121-75-5	20-May-16	<a href="#">180</a>
Malonaldehyde, sodium salt	cancer	<a href="#">AB</a>	24382-04-5	03-May-11	
Mancozeb	cancer	AB	8018-01-7	01-Jan-90	
Maneb	cancer	AB	12427-38-2	01-Jan-90	
Marijuana smoke	cancer	<a href="#">SQE</a>	---	19-Jun-09	
Me-A-alpha-C (2-Amino-3-methyl-9H-pyrido[2,3-b]indole)	cancer	AB	68006-83-7	01-Jan-90	<a href="#">0.6</a>
Mebendazole	developmental	<a href="#">FR</a>	31431-39-7	20-Aug-99	
Medroxyprogesterone acetate	cancer	AB	71-58-9	01-Jan-90	
Medroxyprogesterone acetate	developmental	FR	71-58-9	01-Apr-90	
Megestrol acetate	cancer	<a href="#">FR</a>	595-33-5	28-Mar-14	
Megestrol acetate	developmental	FR	595-33-5	01-Jan-91	
MelQ (2-Amino-3,4-dimethylimidazo[4,5-f]quinoline)	cancer	AB	77094-11-2	01-Oct-94	<a href="#">0.46</a>
MelQx (2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline)	cancer	AB	77500-04-0	01-Oct-94	<a href="#">0.41</a>
Melphalan	cancer	LC	148-82-3	27-Feb-87	<a href="#">0.005</a>



# PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.

Page **14** of **23**

Issue Date:  
11/09/2023

Document Owner:  
H. Evans

Melphalan	developmental	FR	148-82-3	01-Jul-90	
Menotropins	developmental	FR	9002-68-0	01-Apr-90	
Mepanipyrim	cancer	<a href="#">AB</a>	110235-47-7	01-Jul-08	
Meprobamate	developmental	FR	57-53-4	01-Jan-92	
2-Mercaptobenzothiazole	cancer	<a href="#">LC</a>	149-30-4	27-Oct-17	
Mercaptopurine	developmental	FR	6112-76-1	01-Jul-90	
Mercury and mercury compounds	developmental	AB	---	01-Jul-90	
Merphalan	cancer	SQE	531-76-0	01-Apr-88	
Mestranol	cancer	SQE	72-33-3	01-Apr-88	
Metam potassium	cancer	<a href="#">AB</a>	137-41-7	31-Dec-10	
Methacycline hydrochloride	developmental	FR	3963-95-9	01-Jan-91	
Metham sodium	cancer	<a href="#">AB</a>	137-42-8	06-Nov-98	
Metham sodium	developmental	<a href="#">AB</a>	137-42-8	15-May-98	<a href="#">290</a>
Methanol	developmental	<a href="#">AB</a>	67-56-1	16-Mar-12	<a href="#">47,000 (inhalation)</a> <a href="#">23,000 (oral)</a>
Methazole	developmental	<a href="#">AB</a>	20354-26-1	01-Dec-99	
Methimazole	developmental	FR	60-56-0	01-Jul-90	
Methotrexate	developmental	SQE	59-05-2	01-Jan-89	
Methotrexate sodium	developmental	FR	15475-56-6	01-Apr-90	
5-Methoxypsoralen with ultraviolet A therapy	cancer	SQE	484-20-8	01-Oct-88	
8-Methoxypsoralen with ultraviolet A therapy	cancer	LC	298-81-7	27-Feb-87	
Methyl acrylate	cancer	<a href="#">LC</a>	96-33-3	17-Dec-21	
2-Methylaziridine (Propyleneimine)	cancer	SQE	75-55-8	01-Jan-88	<a href="#">0.028</a>
Methylazoxymethanol	cancer	SQE	590-96-5	01-Apr-88	
Methylazoxymethanol acetate	cancer	SQE	592-62-1	01-Apr-88	
Methyl bromide, as a structural fumigant	developmental	FR	74-83-9	01-Jan-93	<a href="#">810 (inhalation)</a>
Methyl carbamate	cancer	<a href="#">AB</a>	598-55-0	15-May-98	<a href="#">160</a>
Methyl chloride	developmental	<a href="#">AB</a>	74-87-3	10-Mar-00	
Methyl chloride [Basis for listing changed effective March 7, 2014]	male	<a href="#">AB</a>	74-87-3	07-Aug-09	
3-Methylcholanthrene	cancer	AB	56-49-5	01-Jan-90	<a href="#">0.03</a>
5-Methylchrysene	cancer	SQE	3697-24-3	01-Apr-88	<a href="#">0.0084 (oral)</a>
4,4'-Methylene bis(2-chloroaniline)	cancer	FR	101-14-4	01-Jul-87	<a href="#">0.5</a>
4,4'-Methylene bis(N,N-dimethyl)benzenamine	cancer	LC	101-61-1	01-Oct-89	20
4,4'-Methylene bis(2-methylaniline)	cancer	SQE	838-88-0	01-Apr-88	<a href="#">0.8</a>
4,4'-Methylenedianiline	cancer	SQE	101-77-9	01-Jan-88	<a href="#">0.4</a>
4,4'-Methylenedianiline dihydrochloride	cancer	SQE	13552-44-8	01-Jan-88	<a href="#">0.6</a>
Methyleugenol	cancer	<a href="#">AB</a>	93-15-2	16-Nov-01	
Methylhydrazine and its salts	cancer	AB	---	01-Jul-92	
Methylhydrazine					<a href="#">0.058 (oral)</a> <a href="#">0.090 (inhalation)</a>
Methylhydrazine sulfate					<a href="#">0.18</a>
2-Methylimidazole	cancer	<a href="#">LC</a>	693-98-1	22-Jun-12	
4-Methylimidazole	cancer	<a href="#">AB</a>	822-36-6	07-Jan-11	<a href="#">29</a>
Methyl iodide	cancer	SQE	74-88-4	01-Apr-88	
Methyl isobutyl ketone	cancer	<a href="#">LC</a>	108-10-1	04-Nov-11	
Methyl isobutyl ketone (MIBK)	developmental	<a href="#">AB</a>	108-10-1	28-Mar-14	
Methyl isocyanate (MIC)	developmental, female	<a href="#">SQE</a>	624-83-9	12-Nov-10	
<a href="#">Methyl isopropyl ketone Delisted April 4, 2014 [Click for the basis for delisting]</a>	developmental	<a href="#">LC</a>	563-80-4	17-Feb-12	
Methyl mercury	developmental	SQE	---	01-Jul-87	
Methylmercury compounds	cancer	AB	---	01-May-96	
Methyl methanesulfonate	cancer	SQE	66-27-3	01-Apr-88	<a href="#">7</a>
Methyl-n-butyl ketone	developmental	<a href="#">SQE</a>	591-78-6	04-Dec-15	
Methyl-n-butyl ketone [Basis for listing changed effective November 9, 2015]	male	SQE	591-78-6	07-Aug-09	
2-Methyl-1-nitroanthraquinone (of uncertain purity)	cancer	SQE	129-15-7	01-Apr-88	<a href="#">0.2</a>



# PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.

Page **15** of **23**

Issue Date:  
11/09/2023

Document Owner:  
H. Evans

N-Methyl-N'-nitro-N-nitrosoguanidine	cancer	SQE	70-25-7	01-Apr-88	<a href="#">0.08</a>
N-Methylolacrylamide	cancer	AB	924-42-5	01-Jul-90	
N-Methylpyrrolidone	developmental	<a href="#">AB</a>	872-50-4	15-Jun-01	<a href="#">3200 (inhalation)</a> <a href="#">17000 (dermal)</a>
α-Methyl styrene (alpha-Methylstyrene)	cancer	<a href="#">LC</a>	98-83-9	02-Nov-12	
<a href="#">α-Methyl styrene Delisted April 4, 2014 (Click for the basis for delisting)</a>	female	<a href="#">LC</a>	98-83-9	29-Jul-11	
Methyltestosterone	developmental	FR	58-18-4	01-Apr-90	
Methylthiouracil	cancer	LC	56-04-2	01-Oct-89	<a href="#">2</a>
Metiram	cancer	AB	9006-42-2	01-Jan-90	
Metiram	developmental	<a href="#">AB</a>	9006-42-2	30-Mar-99	
Metronidazole	cancer	SQE	443-48-1	01-Jan-88	
Michler's ketone	cancer	SQE	90-94-8	01-Jan-88	<a href="#">0.8</a>
Midazolam hydrochloride	developmental	FR	59467-96-8	01-Jul-90	
Minocycline hydrochloride (internal use)	developmental	FR	13614-98-7	01-Jan-92	
Mirex	cancer	SQE	2385-85-5	01-Jan-88	<a href="#">0.04</a>
Misoprostol	developmental	FR	59122-46-2	01-Apr-90	
Mitomycin C	cancer	SQE	50-07-7	01-Apr-88	<a href="#">0.00009</a>
Mitoxantrone hydrochloride	cancer	<a href="#">FR</a>	70476-82-3	23-Jan-15	
Mitoxantrone hydrochloride	developmental	FR	70476-82-3	01-Jul-90	
Molinate	developmental, female, male	<a href="#">AB</a>	2212-67-1	11-Dec-09	
Molybdenum trioxide	cancer	<a href="#">LC</a>	1313-27-5	19-Mar-21	
MON 4660 (dichloroacetyl-1-oxa-4-azaspiro(4,5)-decane)	cancer	<a href="#">AB</a>	71526-07-3	22-Mar-11	
MON 13900 (furylazole)	cancer	<a href="#">AB</a>	121776-33-8	22-Mar-11	
3-Monochloropropane-1,2-diol (3-MCPD)	cancer	<a href="#">SQE</a>	96-24-2	08-Oct-10	
Monocrotaline	cancer	SQE	315-22-0	01-Apr-88	<a href="#">0.07</a>
MOPP (vincristine-prednisone-nitrogen mustard-procarbazine mixture)	cancer	<a href="#">LC</a>	113803-47-7	04-Nov-11	
5-(Morpholinomethyl)-3-[[5-nitrofurfuryl-iden]-amino]-2-oxazolidinone	cancer	SQE	139-91-3	01-Apr-88	<a href="#">0.18</a>
Mustard Gas	cancer	LC	505-60-2	27-Feb-87	
MX (3-chloro-4-dichloromethyl-5-hydroxy-2(5H)-furanone)	cancer	<a href="#">SQE</a>	77439-76-0	22-Dec-00	<a href="#">0.11</a>
Myclobutanil	developmental, male	<a href="#">AB</a>	88671-89-0	16-Apr-99	
beta-Myrcene	cancer	<a href="#">AB</a>	123-35-3	27-Mar-15	
Nabam	developmental	<a href="#">AB</a>	142-59-6	30-Mar-99	
Nafarelin acetate	developmental	FR	86220-42-0	01-Apr-90	
Nafenopin	cancer	SQE	3771-19-5	01-Apr-88	
Nalidixic acid	cancer	<a href="#">AB</a>	389-08-2	15-May-98	<a href="#">28</a>
Naphthalene	cancer	<a href="#">AB</a>	91-20-3	19-Apr-02	<a href="#">5.8</a>
1-Naphthylamine	cancer	LC	134-32-7	01-Oct-89	
2-Naphthylamine	cancer	LC	91-59-8	27-Feb-87	<a href="#">0.4</a>
Neomycin sulfate (internal use)	developmental	FR	1405-10-3	01-Oct-92	
Netilmicin sulfate	developmental	FR	56391-57-2	01-Jul-90	
Nickel (Metallic)	cancer	LC	7440-02-0	01-Oct-89	
Nickel acetate	cancer	LC	373-02-4	01-Oct-89	
Nickel carbonate	cancer	LC	3333-67-3	01-Oct-89	
Nickel carbonyl	cancer	SQE	13463-39-3	01-Oct-87	
Nickel carbonyl	developmental	AB	13463-39-3	01-Sep-96	
Nickel compounds	cancer	<a href="#">LC</a>	---	07-May-04	
Nickel (soluble compounds)	developmental, male	<a href="#">SQE</a>	---	26-Oct-18	
Nickel hydroxide	cancer	LC	12054-48-7; 12125-56-3	01-Oct-89	
Nickelocene	cancer	LC	1271-28-9	01-Oct-89	
Nickel oxide	cancer	LC	1313-99-1	01-Oct-89	
Nickel refinery dust from the pyrometallurgical process	cancer	SQE	---	01-Oct-87	0.8





# PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.

Page **16** of **23**

Issue Date:  
11/09/2023

Document Owner:  
H. Evans

Nickel subsulfide	cancer	SQE	12035-72-2	01-Oct-87	0.4
Nicotine	developmental	FR	54-11-5	01-Apr-90	
Nifedipine	developmental, female, male	<a href="#">FR</a>	21829-25-4	29-Jan-99	
Nimodipine	developmental	<a href="#">FR</a>	66085-59-4	24-Apr-01	
Niridazole	cancer	SQE	61-57-4	01-Apr-88	
Nitrapyrin [Basis for listing changed effective on November 4, 2015]	cancer	SQE	1929-82-4	05-Oct-05	
Nitrapyrin	developmental	<a href="#">AB</a>	1929-82-4	30-Mar-99	
Nitrilotriacetic acid	cancer	SQE	139-13-9	01-Jan-88	<a href="#">100</a>
Nitrilotriacetic acid, trisodium salt monohydrate	cancer	SQE	18662-53-8	01-Apr-89	<a href="#">70</a>
5-Nitroacenaphthene	cancer	SQE	602-87-9	01-Apr-88	<a href="#">6</a>
<a href="#">5-Nitro-o-anisidine Delisted December 8, 2006 [Click here for the basis for delisting]</a>	cancer	LC	99-59-2	01-Oct-89	10
o-Nitroanisole	cancer	AB	91-23-6	01-Oct-92	
para-Nitroanisole	cancer	<a href="#">LC</a>	100-17-4	13-Sep-19	
Nitrobenzene	cancer	<a href="#">AB</a>	98-95-3	26-Aug-97	
Nitrobenzene	male	<a href="#">AB</a>	98-95-3	30-Mar-10	
4-Nitrobiphenyl	cancer	SQE	92-93-3	01-Apr-88	
6-Nitrochrysene	cancer	AB	7496-02-8	01-Oct-90	
Nitrofen (technical grade)	cancer	SQE	1836-75-5	01-Jan-88	<a href="#">9</a>
2-Nitrofluorene	cancer	AB	607-57-8	01-Oct-90	
Nitrofurantoin	male	AB	67-20-9	01-Apr-91	
Nitrofurazone	cancer	AB	59-87-0	01-Jan-90	<a href="#">0.5</a>
1-[(5-Nitrofurfurylidene)-amino]-2-imidazolidinone	cancer	SQE	555-84-0	01-Apr-88	<a href="#">0.4</a>
N-[4-(5-Nitro-2-furyl)-2-thiazolyl]acetamide	cancer	SQE	531-82-8	01-Apr-88	<a href="#">0.5</a>
Nitrogen mustard (Mechlorethamine)	cancer	SQE	51-75-2	01-Jan-88	
Nitrogen mustard (Mechlorethamine)	developmental	SQE	51-75-2	01-Jan-89	
Nitrogen mustard hydrochloride (Mechlorethamine hydrochloride)	cancer	SQE	55-86-7	01-Apr-88	
Nitrogen mustard hydrochloride (Mechlorethamine hydrochloride)	developmental	FR	55-86-7	01-Jul-90	
Nitrogen mustard N-oxide	cancer	SQE	126-85-2	01-Apr-88	
Nitrogen mustard N-oxide hydrochloride	cancer	SQE	302-70-5	01-Apr-88	
Nitromethane	cancer	<a href="#">AB</a>	75-52-5	01-May-97	<a href="#">39</a>
2-Nitropropane	cancer	SQE	79-46-9	01-Jan-88	
1-Nitropyrene	cancer	AB	5522-43-0	01-Oct-90	
4-Nitropyrene	cancer	AB	57835-92-4	01-Oct-90	
N-Nitrosodi-n-butylamine	cancer	SQE	924-16-3	01-Oct-87	0.06
N-Nitrosodiethanolamine	cancer	SQE	1116-54-7	01-Jan-88	0.3
N-Nitrosodiethylamine	cancer	SQE	55-18-5	01-Oct-87	0.02
N-Nitrosodimethylamine	cancer	SQE	62-75-9	01-Oct-87	0.04
p-Nitrosodiphenylamine	cancer	SQE	156-10-5	01-Jan-88	<a href="#">30</a>
N-Nitrosodiphenylamine	cancer	SQE	86-30-6	01-Apr-88	80
N-Nitrosodi-n-propylamine	cancer	SQE	621-64-7	01-Jan-88	0.1
N-Nitroso-N-ethylurea	cancer	SQE	759-73-9	01-Oct-87	0.03
N-Nitrosohexamethyleneimine	cancer	SQE	932-83-2	23-Nov-18	
3-(N-Nitrosomethylamino) propionitrile	cancer	AB	60153-49-3	01-Apr-90	
4-(N-Nitrosomethylamino)-1-(3-pyridyl)1-butanone	cancer	AB	64091-91-4	01-Apr-90	<a href="#">0.014</a>
N-Nitrosomethyl-n-butylamine	cancer	<a href="#">SQE</a>	7068-83-9	26-Dec-14	
N-Nitrosomethyl-n-decylamine	cancer	<a href="#">SQE</a>	75881-22-0	26-Dec-14	
N-Nitrosomethyl-n-dodecylamine	cancer	<a href="#">SQE</a>	55090-44-3	26-Dec-14	
N-Nitrosomethylethylamine	cancer	LC	10595-95-6	01-Oct-89	0.03
N-Nitrosomethyl-n-heptylamine	cancer	<a href="#">SQE</a>	16338-99-1	26-Dec-14	
N-Nitrosomethyl-n-hexylamine	cancer	<a href="#">SQE</a>	28538-70-7	26-Dec-14	
N-Nitrosomethyl-n-nonylamine	cancer	<a href="#">SQE</a>	75881-19-5	26-Dec-14	
N-Nitrosomethyl-n-octylamine	cancer	<a href="#">SQE</a>	34423-54-6	26-Dec-14	
N-Nitrosomethyl-n-pentylamine	cancer	<a href="#">SQE</a>	13256-07-0	26-Dec-14	
N-Nitrosomethyl-n-propylamine	cancer	<a href="#">SQE</a>	924-46-9	26-Dec-14	
N-Nitrosomethyl-n-tetradecylamine	cancer	<a href="#">SQE</a>	75881-20-8	26-Dec-14	



# PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.

Page **17** of **23**

Issue Date:  
11/09/2023

Document Owner:  
H. Evans

N-Nitrosomethyl-n-undecylamine	cancer	<a href="#">SQE</a>	68107-26-6	26-Dec-14	
N-Nitroso-N-methylurea	cancer	SQE	684-93-5	01-Oct-87	0.006
N-Nitroso-N-methylurethane	cancer	SQE	615-53-2	01-Apr-88	<a href="#">0.006</a>
N-Nitrosomethylvinylamine	cancer	SQE	4549-40-0	01-Jan-88	
N-Nitrosomorpholine	cancer	SQE	59-89-2	01-Jan-88	<a href="#">0.1</a>
N-Nitrosornicotine	cancer	SQE	16543-55-8	01-Jan-88	<a href="#">0.5</a>
N-Nitrosopiperidine	cancer	SQE	100-75-4	01-Jan-88	<a href="#">0.07</a>
N-Nitrosopyrrolidine	cancer	SQE	930-55-2	01-Oct-87	0.3
N-Nitrososarcosine	cancer	SQE	13256-22-9	01-Jan-88	
o-Nitrotoluene	cancer	<a href="#">AB</a>	88-72-2	15-May-98	
Nitrous oxide [Basis for listing changed effective November 8, 2013]	developmental, female	<a href="#">AB</a>	10024-97-2	01-Aug-08	
Norethisterone (Norethindrone)	cancer	LC	68-22-4	01-Oct-89	
Norethisterone (Norethindrone)	developmental	FR	68-22-4	01-Apr-90	
Norethisterone acetate (Norethindrone acetate)	developmental	FR	51-98-9	01-Oct-91	
Norethisterone (Norethindrone) /Ethinyl estradiol	developmental	FR	68-22-4/ 57-63-6	01-Apr-90	
Norethisterone (Norethindrone) /Mestranol	developmental	FR	68-22-4/ 72-33-3	01-Apr-90	
Norethynodrel	cancer	<a href="#">AB</a>	68-23-5	27-Feb-01	
Norgestrel	developmental	FR	6533-00-2	01-Apr-90	
Ochratoxin A	cancer	AB	303-47-9	01-Jul-90	
Oil Orange SS	cancer	SQE	2646-17-5	01-Apr-88	
Oral contraceptives, combined	cancer	LC	---	01-Oct-89	
Oral contraceptives, sequential	cancer	LC	---	01-Oct-89	
Oryzalin	cancer	<a href="#">AB</a>	19044-88-3	12-Sep-08	
Oxadiazon	cancer	SQE	19666-30-9	01-Jul-91	
Oxadiazon	developmental	<a href="#">AB</a>	19666-30-9	15-May-98	
Oxazepam	cancer	AB	604-75-1	01-Oct-94	
Oxazepam	developmental	FR	604-75-1	01-Oct-92	
<a href="#">p,p'-Oxybis(benzenesulfonyl hydrazide)</a> <a href="#">Delisted December 13, 2013 [Click here for the basis for delisting]</a>	developmental	LC	<del>80-51-3</del>	<del>07-Aug-09</del>	
Oxydemeton methyl	female, male	<a href="#">AB</a>	301-12-2	06-Nov-98	
Oxymetholone	cancer	SQE	434-07-1	01-Jan-88	
Oxymetholone	developmental	<a href="#">FR</a>	434-07-1	01-May-97	
Oxytetracycline (internal use)	developmental	FR	79-57-2	01-Jan-91	
Oxytetracycline hydrochloride (internal use)	developmental	FR	2058-46-0	01-Oct-91	
Oxythioquinox (Chinomethionat)	cancer	<a href="#">AB</a>	2439-01-2	20-Aug-99	
Oxythioquinox (Chinomethionat)	developmental	<a href="#">AB</a>	2439-01-2	06-Nov-98	
Paclitaxel	developmental, female, male	<a href="#">FR</a>	33069-62-4	26-Aug-97	
Palygorskite fibers (> 5µm in length)	cancer	<a href="#">AB</a>	12174-11-7	28-Dec-99	
Panfuran S	cancer	SQE	794-93-4	01-Jan-88	
Paramethadione	developmental	FR	115-67-3	01-Jul-90	
Parathion	cancer	<a href="#">LC</a>	56-38-2	20-May-16	
Penicillamine	developmental	FR	52-67-5	01-Jan-91	
pentabromodiphenyl ether mixture [DE-71 (technical grade)]	cancer	<a href="#">AB</a>	---	07-Jul-17	
Pentachlorophenol	cancer	AB	87-86-5	01-Jan-90	40
Pentachlorophenol and by-products of its synthesis (complex mixture)	cancer	<a href="#">AB</a>	---	21-Oct-16	
Pentobarbital sodium	developmental	FR	57-33-0	01-Jul-90	
Pentosan polysulfate sodium	cancer	<a href="#">LC</a>	---	18-Apr-14	
Pentostatin	developmental	FR	53910-25-1	01-Sep-96	
Perfluorononanoic acid (PFNA) and its salts	male	SQE	---	31-Dec-21	
Perfluorooctane sulfonate (PFOS)	developmental	<a href="#">AB</a>	1763-23-1	10-Nov-17	
Perfluorooctane sulfonic acid (PFOS) and its salts and transformation and degradation precursors	cancer	SQE	---	24-Dec-21	



# PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.

Page **18** of **23**

Issue Date:  
11/09/2023

Document Owner:  
H. Evans

Perfluorooctanoic acid (PFOA)	cancer	<a href="#">AB</a>	335-67-1	25-Feb-22	
Perfluorooctanoic acid (PFOA)	developmental	<a href="#">AB</a>	335-67-1	10-Nov-17	
Pertuzumab	developmental	<a href="#">FR</a>	380610-27-5	27-Jan-17	
Phenacetin	cancer	<a href="#">LC</a>	62-44-2	01-Oct-89	<a href="#">300</a>
Phenazopyridine	cancer	<a href="#">SQE</a>	94-78-0	01-Jan-88	<a href="#">4</a>
Phenazopyridine hydrochloride	cancer	<a href="#">SQE</a>	136-40-3	01-Jan-88	<a href="#">5</a>
Phenesterin	cancer	<a href="#">SQE</a>	3546-10-9	01-Jul-89	<a href="#">0.005</a>
Phenobarbital	cancer	<a href="#">AB</a>	50-06-6	01-Jan-90	<a href="#">2</a>
Phenolphthalein	cancer	<a href="#">AB</a>	77-09-8	15-May-98	
Phenoxybenzamine	cancer	<a href="#">SQE</a>	59-96-1	01-Apr-88	<a href="#">0.2</a>
Phenoxybenzamine hydrochloride	cancer	<a href="#">SQE</a>	63-92-3	01-Apr-88	<a href="#">0.3</a>
Phenprocoumon	developmental	<a href="#">FR</a>	435-97-2	01-Oct-92	
o-Phenylenediamine and its salts	cancer	<a href="#">AB</a>	95-54-5	15-May-98	
o-Phenylenediamine					<a href="#">26</a>
o-Phenylenediamine dihydrochloride					<a href="#">44</a>
Phenyl glycidyl ether	cancer	<a href="#">AB</a>	122-60-1	01-Oct-90	<a href="#">5</a>
<a href="#">Phenyl glycidyl ether Delisted April 4, 2014 [Click here for the basis for delisting]</a>	male	<a href="#">LC</a>	122-60-1	07-Aug-09	
Phenyldiazine and its salts	cancer	<a href="#">AB</a>	---	01-Jul-92	
Phenyldiazine					<a href="#">1</a>
Phenyldiazine hydrochloride					<a href="#">1.4</a>
o-Phenylphenate, sodium	cancer	<a href="#">AB</a>	132-27-4	01-Jan-90	<a href="#">200</a>
o-Phenylphenol	cancer	<a href="#">AB</a>	90-43-7	04-Aug-00	
Phenylphosphine [Basis for listing changed effective June 6, 2014]	developmental male	<a href="#">LC SQE</a>	638-21-1	07-Aug-09	
PhiP(2-Amino-1-methyl-6- phenylimidazol[4,5-b]pyridine)	cancer	<a href="#">AB</a>	105650-23-5	01-Oct-94	
Pimozide	developmental, female	<a href="#">FR</a>	2062-78-4	20-Aug-99	
Pioglitazone	cancer	<a href="#">LC</a>	111025-46-8	18-Apr-14	
Pipobroman	developmental	<a href="#">FR</a>	54-91-1	01-Jul-90	
Pirimicarb	cancer	<a href="#">AB</a>	23103-98-2	01-Jul-08	
Plicamycin	developmental	<a href="#">FR</a>	18378-89-7	01-Apr-90	
Polybrominated biphenyls	cancer	<a href="#">SQE</a>	---	01-Jan-88	0.02
Polybrominated biphenyls	developmental	<a href="#">AB</a>	---	01-Oct-94	
Polychlorinated biphenyls	cancer	<a href="#">LC</a>	---	01-Oct-89	0.09
Polychlorinated biphenyls	developmental	<a href="#">SQE</a>	---	01-Jan-91	
Polychlorinated biphenyls (containing 60 or more percent chlorine by molecular weight)	cancer	<a href="#">SQE</a>	---	01-Jan-88	
Polychlorinated dibenzo-p-dioxins	cancer	<a href="#">FR</a>	---	01-Oct-92	
Polychlorinated dibenzofurans	cancer	<a href="#">FR</a>	---	01-Oct-92	
Polygeenan	cancer	<a href="#">SQE</a>	53973-98-1	01-Jan-88	<a href="#">1200</a>
Ponceau MX	cancer	<a href="#">SQE</a>	3761-53-3	01-Apr-88	<a href="#">200</a>
Ponceau 3R	cancer	<a href="#">SQE</a>	3564-09-8	01-Apr-88	<a href="#">40</a>
Potassium bromate	cancer	<a href="#">AB</a>	7758-01-2	01-Jan-90	<a href="#">1</a>
Potassium dimethyldithiocarbamate	developmental	<a href="#">AB</a>	128-03-0	30-Mar-99	<a href="#">720</a>
Pravastatin sodium	developmental	<a href="#">FR</a>	81131-70-6	03-Mar-00	
Prednisolone sodium phosphate	developmental	<a href="#">FR</a>	125-02-0	20-Aug-99	
Primidone	cancer	<a href="#">AB</a>	125-33-7	20-Aug-99	
Procarbazine	cancer	<a href="#">SQE</a>	671-16-9	01-Jan-88	<a href="#">0.05</a>
Procarbazine hydrochloride	cancer	<a href="#">SQE</a>	366-70-1	01-Jan-88	<a href="#">0.06</a>
Procarbazine hydrochloride	developmental	<a href="#">FR</a>	366-70-1	01-Jul-90	
Procymidone	cancer	<a href="#">AB</a>	32809-16-8	01-Oct-94	
Progesterone	cancer	<a href="#">SQE</a>	57-83-0	01-Jan-88	
Pronamide	cancer	<a href="#">AB</a>	23950-58-5	01-May-96	
Propachlor	cancer	<a href="#">AB</a>	1918-16-7	27-Feb-01	
1,3-Propane sultone	cancer	<a href="#">SQE</a>	1120-71-4	01-Jan-88	<a href="#">0.3</a>
Propargite	cancer	<a href="#">AB</a>	2312-35-8	01-Oct-94	
Propargite	developmental	<a href="#">AB</a>	2312-35-8	15-Jun-99	
Propazine	developmental, female	<a href="#">AB</a>	139-40-2	15-Jul-16	<a href="#">100 (oral)</a>
beta-Propiolactone	cancer	<a href="#">SQE</a>	57-57-8	01-Jan-88	<a href="#">0.05</a>



# PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.

Page **19** of **23**

Issue Date:  
11/09/2023

Document Owner:  
H. Evans

Propoxur	cancer	<a href="#">AB</a>	114-26-1	11-Aug-06	
Propylene glycol mono-t-butyl ether	cancer	<a href="#">AB</a>	57018-52-7	11-Jun-04	
Propylene oxide	cancer	SQE	75-56-9	01-Oct-88	
Propylthiouracil	cancer	SQE	51-52-5	01-Jan-88	<a href="#">0.7</a>
Propylthiouracil	developmental	FR	51-52-5	01-Jul-90	
Pulegone	cancer	<a href="#">LC</a>	89-82-7	18-Apr-14	
Pymetrozine	cancer	<a href="#">AB</a>	123312-89-0	22-Mar-11	
Pyridine	cancer	<a href="#">AB</a>	110-86-1	17-May-02	
Pyrimethamine	developmental	<a href="#">FR</a>	58-14-0	29-Jan-99	
Quazepam	developmental	<a href="#">FR</a>	36735-22-5	26-Aug-97	
Quinoline and its strong acid salts	cancer	<a href="#">SQE</a>	---	24-Oct-97	
Quizalofop-ethyl	male	<a href="#">SQE</a>	76578-14-8	24-Dec-99	<a href="#">590</a>
Radionuclides	cancer	SQE	---	01-Jul-89	
Reserpine	cancer	LC	50-55-5	01-Oct-89	<a href="#">0.06</a>
Residual (heavy) fuel oils	cancer	AB	---	01-Oct-90	
Resmethrin	cancer	<a href="#">AB</a>	10453-86-8	01-Jul-08	
Resmethrin	developmental	<a href="#">AB</a>	10453-86-8	06-Nov-98	
Retinol/retinyl esters, when in daily dosages in excess of 10,000 IU, or 3,000 retinol equivalents. (NOTE: Retinol/retinyl esters are required and essential for maintenance of normal reproductive function. The recommended daily level during pregnancy is 8,000 IU.)	developmental	SQE	---	01-Jul-89	
Ribavirin	developmental	FR	36791-04-5	01-Apr-90	
Ribavirin	male	<a href="#">FR</a>	36791-04-5	27-Feb-01	
Riddelliine	cancer	<a href="#">LC</a>	23246-96-0	03-Dec-04	
Rifampin	developmental, female	<a href="#">FR</a>	13292-46-1	27-Feb-01	
<a href="#">Saccharin - Delisted April 6, 2001 - [Click here for the basis for delisting]</a>	cancer	LC	81-07-2	01-Oct-89	
<a href="#">Saccharin, sodium - Delisted January 17, 2003 [Click here for the basis for delisting]</a>	cancer	SQE	128-44-9	01-Jan-88	
Safrole	cancer	SQE	94-59-7	01-Jan-88	<a href="#">3</a>
Salted fish, Chinese-style	cancer	<a href="#">LC</a>	---	29-Apr-11	
Secobarbital sodium	developmental	FR	309-43-3	01-Oct-92	
Sedaxane	cancer	<a href="#">AB</a>	874967-67-6	01-Jul-16	
Selenium sulfide	cancer	LC	7446-34-6	01-Oct-89	
Sermorelin acetate	developmental	<a href="#">FR</a>	---	20-Aug-99	
Shale-oils	cancer	AB	68308-34-9	01-Apr-90	
Silica, crystalline (airborne particles of respirable size)	cancer	SQE	---	01-Oct-88	
Simazine	developmental, female	<a href="#">AB</a>	122-34-9	15-Jul-16	<a href="#">100 (oral)</a>
Sodium dimethyldithiocarbamate	developmental	<a href="#">AB</a>	128-04-1	30-Mar-99	<a href="#">23 (oral)</a> <a href="#">58 (oral) as a 40% pesticidal formulation</a>
Sodium fluoroacetate	male	<a href="#">AB</a>	62-74-8	06-Nov-98	
Soots, tars, and mineral oils (untreated and mildly treated oils and used engine oils)	cancer	LC	---	27-Feb-87	
Spirodiclofen	cancer	<a href="#">AB</a>	148477-71-8	08-Oct-10	
Spironolactone	cancer	<a href="#">FR</a>	52-01-7	01-May-97	
Stanozolol	cancer	<a href="#">FR</a>	10418-03-8	01-May-97	
Sterigmatocystin	cancer	SQE	10048-13-2	01-Apr-88	<a href="#">0.02</a>
Streptomycin sulfate	developmental	FR	3810-74-0	01-Jan-91	
Streptozocin (streptozotocin)	developmental, female, male	<a href="#">FR</a>	18883-66-4	20-Aug-99	
Streptozotocin (streptozocin)	cancer	SQE	18883-66-4	01-Jan-88	<a href="#">0.006</a>



# PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.

Page **20** of **23**

Issue Date:  
11/09/2023

Document Owner:  
H. Evans

Strong inorganic acid mists containing sulfuric acid	cancer	<a href="#">AB</a>	---	14-Mar-03	
Styrene	cancer	<a href="#">AB</a>	100-42-5	22-Apr-16	<a href="#">27</a>
Styrene oxide	cancer	SQE	96-09-3	01-Oct-88	<a href="#">4</a>
Sulfallate	cancer	SQE	95-06-7	01-Jan-88	<a href="#">4</a>
Sulfasalazine (Salicylazosulfapyridine)	cancer	<a href="#">AB</a>	599-79-1	15-May-98	
Sulfasalazine (Salicylazosulfapyridine)	male	<a href="#">FR</a>	599-79-1	29-Jan-99	
Sulfur dioxide	developmental	<a href="#">SQE</a>	7446-09-5	29-Jul-11	<a href="#">10000</a>
Sulindac	developmental, female	<a href="#">FR</a>	38194-50-2	29-Jan-99	
Talc containing asbestiform fibers	cancer	AB	---	01-Apr-90	
Tamoxifen and its salts	cancer	SQE	10540-29-1	01-Sep-96	
Tamoxifen citrate	developmental	FR	54965-24-1	01-Jul-90	
Temazepam	developmental	FR	846-50-4	01-Apr-90	
Teniposide	developmental	FR	29767-20-2	01-Sep-96	
Terbacil	developmental	<a href="#">AB</a>	5902-51-2	18-May-99	
Teriparatide	cancer	FR	52232-67-4	14-Aug-15	
Terrazole	cancer	AB	2593-15-9	01-Oct-94	
Testosterone and its esters	cancer	SQE	58-22-0	01-Apr-88	
Testosterone cypionate	developmental	FR	58-20-8	01-Oct-91	
Testosterone enanthate	developmental	FR	315-37-7	01-Apr-90	
Tetrabromobisphenol A	cancer	<a href="#">LC</a>	79-94-7	27-Oct-17	
3,3',4,4'-Tetrachloroazobenzene	cancer	<a href="#">AB</a>	14047-09-7	24-Jul-12	
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)	cancer	SQE	1746-01-6	01-Jan-88	0.000005
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)	developmental	AB	1746-01-6	01-Apr-91	
1,1,1,2-Tetrachloroethane	cancer	<a href="#">LC</a>	630-20-6	13-Sep-13	
1,1,1,2-Tetrachloroethane	cancer	AB	79-34-5	01-Jul-90	<a href="#">3</a>
Tetrachloroethylene (Perchloroethylene)	cancer	SQE	127-18-4	01-Apr-88	14
p-a,a,a-Tetrachlorotoluene	cancer	AB	5216-25-1	01-Jan-90	
Tetrachlorvinphos	cancer	<a href="#">LC</a>	22248-79-9	20-May-16	
Tetracycline (internal use)	developmental	FR	60-54-8	01-Oct-91	
Tetracyclines (internal use)	developmental	FR	---	01-Oct-92	
Tetracycline hydrochloride (internal use)	developmental	FR	64-75-5	01-Jan-91	
Tetrafluoroethylene	cancer	<a href="#">AB</a>	116-14-3	01-May-97	
Δ9-Tetrahydrocannabinol (Δ9-THC)	developmental	<a href="#">SQE</a>		03-Jan-20	
Tetrahydrofuran	cancer	<a href="#">LC</a>	109-99-9	17-Dec-21	
Tetranitromethane	cancer	AB	509-14-8	01-Jul-90	<a href="#">0.059</a>
Thalidomide	developmental	SQE	50-35-1	01-Jul-87	
Thioacetamide	cancer	SQE	62-55-5	01-Jan-88	<a href="#">0.1</a>
4,4'-Thiodianiline	cancer	SQE	139-65-1	01-Apr-88	<a href="#">0.05</a>
Thiodicarb	cancer	<a href="#">AB</a>	59669-26-0	20-Aug-99	
Thioguanine	developmental	FR	154-42-7	01-Jul-90	
Thiophanate methyl	female, male	<a href="#">AB</a>	23564-05-8	18-May-99	<a href="#">600 (oral)</a>
Thiouracil	cancer		141-90-2	11-Jun-04	
Thiourea	cancer	SQE	62-56-6	01-Jan-88	<a href="#">10</a>
Thorium dioxide	cancer	LC	1314-20-1	27-Feb-87	
Titanium dioxide (airborne, unbound particles of respirable size)	cancer	<a href="#">LC</a>	---	02-Sep-11	
Tobacco, oral use of smokeless products	cancer	SQE	---	01-Apr-88	
Tobacco smoke	cancer	SQE	---	01-Apr-88	
Tobacco smoke (primary)	developmental, female, male	SQE	---	01-Apr-88	
Tobramycin sulfate	developmental	FR	49842-07-1	01-Jul-90	
Toluene	developmental	SQE	108-88-3	01-Jan-91	7000c
<a href="#">Toluene [Click here for the basis for the removal of female reproductive endpoint effective March 7, 2014]</a>	female	LC	108-88-3	07-Aug-09	
Toluene diisocyanate	cancer	LC	26471-62-5	01-Oct-89	<a href="#">20</a>
o-Toluidine	cancer	SQE	95-53-4	01-Jan-88	<a href="#">4</a>
o-Toluidine hydrochloride	cancer	SQE	636-21-5	01-Jan-88	<a href="#">5</a>



# PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.

Page **21** of **23**

Issue Date:  
11/09/2023

Document Owner:  
H. Evans

<a href="#">para-Toluidine - Delisted October 29, 1999 [Click here for the basis for delisting]</a>	cancer	AB	106-49-0	01-Jan-90	
Topiramate	developmental	<a href="#">FR</a>	97240-79-4	27-Nov-15	
Toxaphene (Polychlorinated camphenes)	cancer	SQE	8001-35-2	01-Jan-88	0.6
Toxins derived from Fusarium moniliforme (Fusarium verticillioides)	cancer	<a href="#">LC</a>	---	07-Aug-09	
Treosulfan	cancer	LC	299-75-2	27-Feb-87	
Triadimefon	developmental, female, male	<a href="#">AB</a>	43121-43-3	30-Mar-99	
Triamterene	cancer	<a href="#">LC</a>	396-01-0	18-Apr-14	
Triazolam	developmental	FR	28911-01-5	01-Apr-90	
S,S,S-Tributyl phosphorothioate (Tribufos, DEF)	cancer	<a href="#">AB</a>	78-48-8	25-Feb-11	
Tributyltin methacrylate	developmental	<a href="#">AB</a>	2155-70-6	01-Dec-99	
Trichlormethine (Trimustine hydrochloride)	cancer	AB	817-09-4	01-Jan-92	
Trichloroacetic acid	cancer	<a href="#">LC</a>	76-03-9	13-Sep-13	<a href="#">9.9</a>
1,1,1-Trichloroethane	cancer	<a href="#">LC</a>	71-55-6	21-Apr-23	
Trichloroethylene	cancer	SQE	79-01-6	01-Apr-88	<a href="#">14 (oral)</a> <a href="#">50 (inhalation)</a>
Trichloroethylene	developmental, male	<a href="#">AB</a>	79-01-6	31-Jan-14	
2,4,6-Trichlorophenol	cancer	SQE	88-06-2	01-Jan-88	10
1,2,3-Trichloropropane	cancer	AB	96-18-4	01-Oct-92	
Trientine hydrochloride	developmental	<a href="#">FR</a>	38260-01-4	27-Feb-01	
Triforine	developmental	<a href="#">AB</a>	26644-46-2	18-Jun-99	
<a href="#">1,3,5-Triglycidyl s triazinetrione - Delisted December 13, 2013 [Click here for the basis for delisting]</a>	male	LC	2451-62-9	07-Aug-09	
Trilostane	developmental	FR	13647-35-3	01-Apr-90	
Trimethadione	developmental	FR	127-48-0	01-Jan-91	
2,4,5-Trimethylaniline and its strong acid salts	cancer	<a href="#">SQE</a>	---	24-Oct-97	
Trimethylolpropane triacrylate, technical grade	cancer	<a href="#">LC</a>	---	17-Dec-21	
Trimethyl phosphate	cancer	AB	512-56-1	01-May-96	<a href="#">24</a>
Trimetrexate glucuronate	developmental	<a href="#">FR</a>	82952-64-5	26-Aug-97	
TRIM® VX	cancer	<a href="#">AB</a>	---	25-May-18	
2,4,6-Trinitrotoluene (TNT)	cancer	<a href="#">SQE</a>	118-96-7	19-Dec-08	<a href="#">8.2</a>
Triphenyltin hydroxide	cancer	AB	76-87-9	01-Jul-92	
Triphenyltin hydroxide	developmental	<a href="#">AB</a>	76-87-9	18-Mar-02	
<a href="#">Tris(aziridinyl) p benzoquinone (Triaziquone) Delisted December 8, 2006 [Click here for the basis for delisting]</a>	cancer	LC	<del>68-76-8</del>	<del>01-Oct-89</del>	
Tris(1-aziridinyl)phosphine sulfide (Thiotepa)	cancer	SQE	52-24-4	01-Jan-88	<a href="#">0.06</a>
Tris(2-chloroethyl) phosphate	cancer	AB	115-96-8	01-Apr-92	
Tris(2,3-dibromopropyl)phosphate	cancer	SQE	126-72-7	01-Jan-88	<a href="#">0.3</a>
Tris(1,3-dichloro-2-propyl) phosphate (TDCPP)	cancer	<a href="#">SQE</a>	13674-87-8	28-Oct-11	<a href="#">5.4</a>
Trp-P-1 (Tryptophan-P-1)	cancer	SQE	62450-06-0	01-Apr-88	<a href="#">0.03</a>
Trp-P-2 (Tryptophan-P-2)	cancer	SQE	62450-07-1	01-Apr-88	<a href="#">0.2</a>
Trypan blue (commercial grade)	cancer	LC	72-57-1	01-Oct-89	
Unleaded gasoline (wholly vaporized)	cancer	SQE	---	01-Apr-88	
Uracil mustard	cancer	SQE	66-75-1	01-Apr-88	
Uracil mustard	developmental, female, male	FR	66-75-1	01-Jan-92	
Urethane (Ethyl carbamate)	cancer	SQE	51-79-6	01-Jan-88	0.7
Urethane (Ethyl carbamate)	developmental	AB	51-79-6	01-Oct-94	
Urofollitropin	developmental	FR	97048-13-0	01-Apr-90	
Valproate (Valproic acid)	developmental	SQE	99-66-1	01-Jul-87	

	<b>PROPOSITION 65 STATEMENT OF CONFORMITY</b>	Document No.
		Page <b>22</b> of <b>23</b>
		Issue Date: 11/09/2023
		Document Owner: H. Evans

Vanadium pentoxide (orthorhombic crystalline form)	cancer	<a href="#">AB</a>	1314-62-1	11-Feb-05	
Vinblastine sulfate	developmental	FR	143-67-9	01-Jul-90	
Vinclozolin [basis for listing changed on November 16, 2006]	cancer	SQE	50471-44-8	20-Aug-99	
Vinclozolin	developmental	<a href="#">AB</a>	50471-44-8	15-May-98	
Vincristine sulfate	developmental	FR	2068-78-2	01-Jul-90	
Vinyl bromide	cancer	SQE	593-60-2	01-Oct-88	
Vinyl chloride	cancer	LC	75-01-4	27-Feb-87	3
4-Vinylcyclohexene	cancer	AB	100-40-3	01-May-96	
<a href="#">4-Vinylcyclohexene [Click here for the basis for the removal of male reproductive endpoint, effective December 20, 2013]</a>	female, <del>male</del>	<a href="#">SQE</a>	100-40-3	07-Aug-09	
4-Vinyl-1-cyclohexene diepoxide (Vinyl cyclohexenedioxide)	cancer	AB	106-87-6	01-Jul-90	
<a href="#">Vinyl cyclohexene dioxide (4-Vinyl-1-cyclohexene diepoxide) [Click here for the basis for the removal of male reproductive endpoint, effective December 20, 2013]</a>	female, <del>male</del>	<a href="#">SQE</a>	106-87-6	01-Aug-08	
Vinyl fluoride	cancer	<a href="#">AB</a>	75-02-5	01-May-97	
Vinylidene chloride (1,1-Dichloroethylene)	cancer	<a href="#">LC</a>	75-35-4	29-Dec-17	<a href="#">0.88</a>
Vinyl trichloride (1,1,2-Trichloroethane)	cancer	AB	79-00-5	01-Oct-90	<a href="#">10</a>
Vismodegib	developmental, female, male	FR	879085-55-9	27-Jan-17	
Warfarin	developmental	SQE	81-81-2	01-Jul-87	
Wood dust	cancer	<a href="#">LC</a>	---	18-Dec-09	
2,6-Xylidine (2,6-Dimethylaniline)	cancer	AB	87-62-7	01-Jan-91	<a href="#">110</a>
Zalcitabine	cancer	<a href="#">LC</a>	7481-89-2	07-Aug-09	
Zidovudine (AZT)	cancer	<a href="#">LC</a>	30516-87-1	18-Dec-09	
Zileuton	cancer, developmental, female	<a href="#">FR</a>	111406-87-2	22-Dec-00	
<a href="#">Zineb -Delisted October 29, 1999 [Click here for the basis for delisting]</a>	<del>cancer</del>	<del>AB</del>	<del>12122-67-7</del>	<del>01-Jan-90</del>	

- a) Where a source or product results in exposures by multiple routes, the total exposure must be considered. For example, the MADL for benzene is exceeded when the absorbed dose exceeds 24 µg/day. If only inhalation and oral exposure occurs, the benzene MADL is exceeded when:  $(\text{oral dose} \div 24 \mu\text{g/day}) + (\text{inhalation dose} \div 49 \mu\text{g/day}) > 1.0$ .
- b) Levels for male children and adolescents were calculated by application of the default bodyweights specified in Section 25703(a)(8) to the procedure specified in Sections 25801 and 25803
- c) Level represents absorbed dose (rounded from 6,525 µg/day). Since 100% of ingested toluene is absorbed, oral dose is equivalent to administered dose. It is assumed that roughly 50% of the dose administered by the inhalation route is absorbed. Therefore, the MADL for inhaled toluene is 13,000 µg/day (rounded from 13,050 µg/day), corresponding to an absorbed dose of 6,525 µg/day.
- d) Butyl benzyl phthalate MADL was adopted June 25, 2013, but pursuant to Government Code section 11343.4 it becomes effective October 1, 2013.
- e) Sulfur dioxide MADL was adopted July 11, 2013, but pursuant to Government Code section 11343.4 it becomes effective October 1, 2013.
- f) Hydrogen cyanide and cyanide salts MADLs were adopted on August 7, 2013, but pursuant to Government Code section 11343.4 they become effective October 1, 2013.



	<b>PROPOSITION 65 STATEMENT OF CONFORMITY</b>	Document No.
		Page <b>23</b> of <b>23</b>
		Issue Date: 11/09/2023
		Document Owner: H. Evans

### Amendment A

In a press release dated 11<sup>th</sup> August 2023, the Office of Environmental Health Hazard Assessment (OEHHA) announced 3 new substances to the list of chemicals known to the State of California to cause cancer under the Safe Drinking Water and Toxic Enforcement Act of 1986, sections 25249.5 et seq. of the Health and Safety Code (HSC), otherwise known as Proposition 65. As of 11<sup>th</sup> August 2023, these substances were formally added to the list, as per list below: -

Chemical	Type of Toxicity	Listing Mechanism	CAS No.	Date Listed	NSRL or MADL (µg/day) <sup>a</sup>
Anthracene	cancer	<a href="#">LC</a>	120-12-7	11-Aug-23	
2-Bromopropane (2-BP)	cancer	<a href="#">LC</a>	75-26-3	11-Aug-23	
Dimethyl hydrogen phosphite	cancer	<a href="#">LC</a>	868-85-9	11-Aug-23	

In a press release dated 17<sup>th</sup> November 2023, the Office of Environmental Health Hazard Assessment (OEHHA) announced 3 new substances to the list of chemicals known to the State of California to cause cancer under the Safe Drinking Water and Toxic Enforcement Act of 1986, sections 25249.5 et seq. of the Health and Safety Code (HSC), otherwise known as Proposition 65. As of 17<sup>th</sup> November 2023, these substances were formally added to the list, as per list below: -


Chemical	Type of Toxicity	Listing Mechanism	CAS No.	Date Listed	NSRL or MADL (µg/day) <sup>a</sup>
Coal-tar pitch	cancer	LC	---	17-Nov-23	
Fluoro-edenite fibrous amphibole	cancer	LC	---	17-Nov-23	
Silicon carbide whiskers	cancer	LC	---	17-Nov-23	

In a press release dated 23<sup>rd</sup> January 2024, the Office of Environmental Health Hazard Assessment (OEHHA) announced 1 new substance to the list of chemicals known to the State of California to cause cancer under the Safe Drinking Water and Toxic Enforcement Act of 1986, sections 25249.5 et seq. of the Health and Safety Code (HSC), otherwise known as Proposition 65. As of 29<sup>th</sup> December 2023, this substance was formally added to the list, as per list below: -

Chemical	Type of Toxicity	Listing Mechanism	CAS No.	Date Listed	NSRL or MADL (µg/day) <sup>a</sup>
Bisphenol S (BPS)	female	<a href="#">SQE</a>	80-09-1	29-Dec-23	

This updated status is based on COIL's understanding of Proposition 65 and COIL knowledge of the 7 new substances that go into its products as of the date of 23<sup>rd</sup> January 2024 disclosure of Proposition 65 compliance.

For and on behalf of  
**COIL Limited**

Signature:		Hollie Evans • Quality Manager	
		Revised:	07 <sup>th</sup> March 2024